キャッスルマン病，TAFRO症候群

出版社： フジメディカル出版
著者：
発行日： 2022-03-10
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784862702500
電子書籍版： 2022-03-10 （第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

8,800 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

6,160 円(税込)

購入する

商品紹介

本書は，キャッスルマン病とTAFRO症候群の最新知見をまとめた初のテキストであり，希少難病の医療アクセス改善もその使命として掲げた成書です。

目次

  • 第1章　キャッスルマン病
    　1．キャッスルマン病の疾患概念
    　2．キャッスルマン病の分類
    　3．キャッスルマン病の病因・病態
    　4．キャッスルマン病の疫学，発生率，統計的事項
    　　1) 全国調査
    　　2) 定点観測（石川県）
    　5．キャッスルマン病の病理
    　6．キャッスルマン病の臨床像と重症度分類
    　7．キャッスルマン病の検査成績
    　　1） 血液検査
    　　2） リンパ節外病変
    　　　(1)肺病変
    　　　(2)皮膚所見
    　　　(3)腎障害，尿所見
    　　3） 多中心性キャッスルマン病のサイトカイン・ケモカイン特性
    　8．キャッスルマン病の診断と鑑別診断
    　9．キャッスルマン病の合併症
    　10．キャッスルマン病の治療
    　11．キャッスルマン病の経過，予後
    　12．キャッスルマン病の関連疾患
    　　1） TAFRO症候群
    　　2） IgG4関連疾患
    　　3） POEMS症候群
    　　4） その他の疾患　腫瘍，膠原病

    第2章　TAFRO症候群
    　1．TAFRO症候群の定義，概念
    　2．TAFRO症候群の病因解明に向けて
    　3．TAFRO症候群の病理―リンパ節病変―
    　4．TAFRO症候群の臨床症状，重症度分類
    　5．TAFRO症候群の検査成績
    　　1） 血液検査
    　　2） リンパ節外病変
    　　　(1) TAFRO症候群の病理―骨髄病変―
    　　　(2) 胸部病変
    　　　(3) 皮膚所見
    　　　(4) TAFRO症候群の腎障害，尿所見
    　　3） その他，特殊検査，遺伝子，Proteomics，Cytokine
    　6．TAFRO症候群の診断
    　7．TAFRO症候群の合併症
    　8．TAFRO症候群の治療
    　9．TAFRO症候群の経過，予後

    第3章　展 望
    　1．キャッスルマン病およびTAFRO症候群の病因・病態探索に向けた試み
    　2．新規治療法の開発
    　3．本邦のキャッスルマン病の診療体制
    　4．国際キャッスルマン病研究組織（CDCN）
    　5．患者会組織

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 キャッスルマン病

P.7 掲載の参考文献
1) Castleman B, Towne VW : CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises : Case 40011. N Engl J Med 250 : 26-30, 1954
 
2) Castleman B, Iverson L, Menendez VP : Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9 : 822-830, 1956
PubMed
3) Abell MR : Lymphnodal hamartoma versus thymic choristoma of pulmonary hilum. AMA Arch Pathol 64 : 584-588, 1957
PubMed
4) Keller AR, Hochholzer L, Castleman B : Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29 : 670-683, 1972
PubMed
5) Hirst E, Williams HB : Intrathoracic lymphoid hamartoma. Thorax 19 : 469-476, 1964
 
6) Lee SL, Rosner F, Rivero I, et al : Refractory anemia with abnormal iron metabolism : Its remission after resection of hyperplastic mediastinal lymph nodes. N Engl J Med 272 : 761-766, 1965
PubMed
7) Neerhout RC, Larson W, Mansur P : Mesenteric lymphoid hamartoma associated with chronic hypoferremia, anemia, growth failure and hyperglobulinemia. N Engl J Med 280 : 922-925, 1969
PubMed
8) Flendrig JA : Het benigne reuzenlymfoom : Een onderzoek naar de correlatie tussen de klinische verschijnselen en de morfologie. Helmond, Holland, Doctorate Thesis, University of Nijmegen, 1969
 
9) Flendrig JA : Benign giant lymphoma : clinicopathologic correlation study ; in Clark RL, Cumley RW (eds) : The year book of cancer. Chicago, Year Book Medical Publishers, 1970, pp296-299
 
10) Anagnostou D, Harrison CV : Angiofollicular lymph node hyperplasia (Castleman). J Clin Pathol 25 : 306-311, 1972
 
11) Gaba AR, Stein RS, Sweet DL, et al : Multicentric giant lymph node hyperplasia. Am J Clin Pathol 69 : 86-90, 1978
PubMed
12) Weisenburger DD : Membranous nephropathy. Its association with multicentric angiofollicular lymph node hyperplasia. Arch Pathol Lab Med 103 : 591-594, 1979
PubMed
13) Bartoli E, Massarelli G, Soggia G, et al : Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol 73 : 423-426, 1980
PubMed
14) 森茂郎, 毛利昇, 内田俊和, ほか : 著しい多クローン性高免疫グロブリン血症と全身リンパ節の高度の形質細胞増生を呈する症候群. 日本網内系学会会誌 20 suppl : 85-94, 1980
 
15) Rizzo SC, Magrini U, Balduini CL, et al : Multicentric giant lymph node hyperplasia. A case report. Haematologica 66 : 673-681, 1981
PubMed
16) Sindram MT, Fedder G : Recurrent and multicentric giant lymph node hyperplasia. Scand J Haematol 27 : 25-29, 1981
PubMed
17) Al-Jabi M, McCaughey WT : Multicentric angiofollicular lymph node hyperplasia. Can Med Assoc J 124 : 1023-1025, 1981
PubMed
18) Frizzera G, Banks PM, Massarelli G, et al : A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol 7 : 211-231, 1983
 
19) Marti S, Pahissa A, Guardia J, et al : Multicentric giant follicular lymph node hyperplasia. Favorable response to radiotherapy. Cancer 51 : 808-810, 1983
PubMed
20) Tanda F, Massarelli G, Costanzi G : Multicentric giant lymph node hyperplasia : an immunohistochemical study. Hum Pathol 14 : 1053-1058, 1983
PubMed
21) Rywlin AM, Rosen L, Cabello B : Coexistence of Castleman's disease and Kaposi's sarcoma. Report of a case and a speculation. Am J Dermatopathol 5 : 277-281, 1983
 
22) Chen KT : Multicentric Castleman's disease and Kaposi's sarcoma. Am J Surg Pathol 8 : 287-293, 1984
 
23) Diebold J, Marche C, Audouin J, et al : Lymph node modification in patients with the acquired immunodeficiency syndrome (AIDS) or with AIDS related complex (ARC). A histological, immuno-histopathological and ultrastructural study of 45 cases. Pathol Res Pract 180 : 590-611, 1985
PubMed
24) Levo Y, Behar AJ, Blum I, et al : A benign course of multicentric Castleman's disease with involvement of the spleen and bone marrow. Eur J Haematol 39 : 471-474, 1987
 
25) Yago K, Kanoh T, Uchino H : Multicentric giant lymph node hyperplasia, plasma cell type, with monoclonal gammopathy. Tohoku J Exp Med 153 : 49-54, 1987
PubMed
26) Ben-Chetrit E, Flusser D, Okon E, et al : Multicentric Castleman's disease associated with rheumatoid arthritis : a possible role of hepatitis B antigen. Ann Rheum Dis 48 : 326-330, 1989
 
27) Mizutani N, Okada S, Tanaka J, et al : Multicentric giant lymph node hyperplasia with ascites and double cancers, an autopsy case. Tohoku J Exp Med 158 : 1-7, 1989
PubMed
28) Frizzera G, Peterson BA, Bayrd ED, et al : A systemic lymphoproliferative disorder with morphologic features of Castleman's disease : clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3 : 1202-1216, 1985
 
29) Frizzera G : Castleman's disease and related disorders. Semin Diagn Pathol 5 : 346-364, 1988
 
30) 森茂郎 : 特殊な悪性リンパ腫IPL (特発性形質細胞性リンパ節症). カレントテラピー 9 : 232-234, 1991
 
31) Crow RS : Peripheral neuritis in myelomatosis. Br Med J 2 : 802-804, 1956
PubMed
32) 深瀬政市, 新保慎一郎, 西谷裕, ほか : 多発性神経炎および内分泌異常を惹起した孤立性骨髄腫. 日本臨床 26 : 2444-2456, 1968
Medical*Online
33) 高月清 : 多発性神経炎, 内分泌症状を伴うPlasma cell dyscrasia. 日本臨床 35 (春季増刊) : 1004-1005, 1977
Medical*Online
34) Takatsuki K, Sanada I : Plasma cell dyscrasia with polyneuropathy and endocrine disorder : clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol 13 : 543-555, 1983
PubMed
35) Nakanishi T, Sobue I, Toyokura Y, et al : The Crow-Fukase syndrome : a study of 102 cases in Japan. Neurology 34 : 712-720, 1984
PubMed
36) Li J, Zhou DB, Huang Z, et al : Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Ann Hematol 90 : 819-826, 2011
PubMed
37) Ulbright TM, Santa Cruz DJ : Kaposi's sarcoma : relationship with hematologic, lymphoid, and thymic neoplasia. Cancer 47 : 963-973, 1981
 
38) Lachant NA, Sun NC, Leong LA, et al : Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol 83 : 27-33, 1985
 
39) Soulier J, Grollet L, Oksenhendler E, et al : Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86 : 1276-1280, 1995
 
40) Gessain A, Sudaka A, Briere J, et al : Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease : is there any relevant association in non-human immunodeficiency virus-infected patients? Blood 87 : 414-416, 1996
 
41) Oksenhendler E, Boutboul D, Fajgenbaum D, et al : The full spectrum of Castleman disease : 273 patients studied over 20 years. Br J Haematol 180 : 206-216, 2018
PubMed
42) Fajgenbaum DC, van Rhee F, Nabel CS : HHV-8-negative, idiopathic multicentric Castleman disease : novel insights into biology, pathogenesis, and therapy. Blood 123 : 2924-2933, 2014
PubMed
43) Kojima M, Nakamura N, Tsukamoto N, et al : Clinical implications of idiopathic multicentric castleman disease among Japanese : a report of 28 cases. Int J Surg Pathol 16 : 391-398, 2008
PubMed
44) 高井和江, 新國公司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
45) Hiramatsu S, Ohmura K, Tsuji H, et al : Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Jpn J Clin Immunol 39 : 64-71, 2016
 
46) Fujiwara S, Mochinaga H, Nakata H, et al : Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol 103 : 718-723, 2016
PubMed
47) Carbone A, Pantanowitz L : TAFRO syndrome : An atypical variant of KSHV-negative multicentric Castleman disease. Am J Hematol 91 : 171-172, 2016
PubMed
48) Tedesco S, Postacchini L, Manfredi L, et al : Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol 4 : 3, 2015
 
49) Tatekawa S, Umemura K, Fukuyama R, et al : Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep 3 : 472-478, 2015
PubMed
50) Konishi Y, Takahashi S, Nishi K, et al : Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A : Possible Pathogenetic Contribution of Interleukin-2. Tohoku J Exp Med 236 : 289-295, 2015
 
51) Kubokawa I, Yachie A, Hayakawa A, et al : The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease. BMC Pediatr 14 : 139, 2014
 
52) Masaki Y, Nakajima A, Iwao H, et al : Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases : is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 53 : 79-85, 2013
 
53) Kawabata H, Kotani S, Matsumura Y, et al : Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 52 : 1503-1507, 2013
 
54) Kawabata H, Takai K, Kojima M, et al : Castleman-Kojima Disease (TAFRO Syndrome) : A Novel Systemic Inflammatory Disease Characterized by a Constellation of Symptoms, Namely, Thrombocytopenia, Ascites (Anasarca), Microcytic Anemia, Myelofibrosis, Renal Dysfunction, and Organomegaly : A Status Report and Summary of Fukushima (6 June, 2012) and Nagoya Meetings (22 September, 2012). J Clin Exp Hematop 53 : 57-61, 2013
 
55) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
56) Fujimoto S, Sakai T, Kawabata H, et al : Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94 : 975-983, 2019
PubMed
57) Yoshizaki K, Matsuda T, Nishimoto N, et al : Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74 : 1360-1367, 1989
 
58) Brandt SJ, Bodine DM, Dunbar CE, et al : Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 86 : 592-599, 1990
 
59) Kojima M, Nakamura N, Tsukamoto N, et al : Atypical lymphoplasmacytic and immunoblastic proliferation of autoimmune disease : clinicopathologic and immunohistochemical study of 9 cases. J Clin Exp Hematop 50 : 113-119, 2010
 
60) Kojima M, Nakamura S, Morishita Y, et al : Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients : a clinicopathological and immunohistological study of 21 cases. Pathol Int 50 : 304-312, 2000
PubMed
61) Rainbow L, Platt GM, Simpson GR, et al : The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol 71 : 5915-5921, 1997
PubMed
62) Dupin N, Diss TL, Kellam P, et al : HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95 : 1406-1412, 2000
PubMed
63) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
PubMed
P.12 掲載の参考文献
1) Bartoli E, Massarelli G, Soggia G, et al : Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol 73 : 423-426, 1980
PubMed
2) Gaba AR, Stein RS, Sweet DL, et al : Multicentric giant lymph node hyperplasia. Am J Clin Pathol 69 : 86-90, 1978
PubMed
3) Frizzera G, Banks PM, Massarelli G, et al : A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol 7 : 211-231, 1983
 
4) Talat N, Schulte KM : Castleman's disease : systematic analysis of 416 patients from the literature. Oncologist 16 : 1316-1324, 2011
 
5) Soulier J, Grollet L, Oksenhendler E, et al : Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86 : 1276-1280, 1995
 
6) Cronin DM, Warnke RA : Castleman disease : an update on classification and the spectrum of associated lesions. Adv Anat Pathol 16 : 236-246, 2009
PubMed
7) Nozza A : POEMS SYNDROME : an Update. Mediterr J Hematol Infect Dis 9 : e2017051, 2017
PubMed
8) Fajgenbaum DC : Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood 132 : 2323-2330, 2018
PubMed
9) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
PubMed
10) Talat N, Belgaumkar AP, Schulte KM : Surgery in Castleman's disease : a systematic review of 404 published cases. Ann Surg 255 : 677-684, 2012
 
11) Li J, Zhou DB, Huang Z et al : Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Ann Hematol 90 : 819-826, 2011
PubMed
12) Kurose N, Futatsuya C, Mizutani KI : The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Hum Pathol 77 : 130-138, 2018
PubMed
13) 吉崎和幸, 岡本真一郎, 川端浩, ほか : キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017
 
P.18 掲載の参考文献
1) Castleman B, Iverson L, Menendez VP : Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9 : 822-830, 1956
PubMed
2) Bartoli E, Massarelli G, Soggia G, et al : Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol 73 : 423-426, 1980
PubMed
3) Yoshizaki K, Matsuda T, Nishimoto N, et al : Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74 : 1360-1367, 1989
 
4) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
PubMed
5) Yoshizaki K : A reference guide for management of Castleman disease. Rinsho Ketsueki 58 : 97-107, 2017
PubMed
6) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : A report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
 
7) Dupin N, Diss TL, Kellam P, et al : HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95 : 1406-1412, 2000
PubMed
8) Bhutani M, Polizzotto MN, Uldrick TS, et al : Kaposi sarcoma-associated herpesvirus-associated malignancies : epidemiology, pathogenesis, and advances in treatment. Semin Oncol 42 : 223-246, 2015
PubMed
9) Hassman LM, Ellison TJ, Kedes DH : KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest 121 : 752-768, 2011
PubMed
10) Mori Y, Nishimoto N, Ohno M, et al : Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. J Med Virol 61 : 332-335, 2000
PubMed
11) Brousset P, Cesarman E, Meggetto F, et al : Colocalization of the viral interleukin-6 with latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells of Kaposi's sarcoma and lymphoid cells of multicentric Castleman's disease. Hum Pathol 32 : 95-100, 2001
 
12) Parravicini C, Chandran B, Corbellino M, et al : Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases : Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 156 : 743-749, 2000
 
13) Parravicini C, Corbellino M, Paulli M, et al : Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 151 : 1517-1522, 1997
 
14) Aoki Y, Narazaki M, Kishimoto T, et al : Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. Blood 98 : 3042-3049, 2001
PubMed
15) Chow D, He X, Snow AL, et al : Structure of an extracellular gp130 cytokine receptor signaling complex. Science 291 : 2150-2155, 2001
PubMed
16) Aoki Y, Jaffe ES, Chang Y, et al : Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93 : 4034-4043, 1999
 
17) Song J, Ohkura T, Sugimoto M, et al : Human interleukin-6 induces human herpesvirus-8 replication in a body cavity-based lymphoma cell line. J Med Virol 68 : 404-411, 2002
 
18) Nishi J, Arimura K, Utsunomiya A, et al : Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol 104 : 482-485, 1999
 
19) Du MQ, Liu H, Diss TC, et al : Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97 : 2130-2136, 2001
PubMed
20) Kone-Paut I, Hentgen V, Guillaume-Czitrom S, et al : The clinical spectrum of 94 patients carrying a single mutated MEFV allele. Rheumatology (Oxford) 48 : 840-842, 2009
PubMed
21) Van Eyck L, Liston A, Meyts I : Mutant ADA2 in vasculopathies. N Engl J Med 371 : 478-479, 2014
PubMed
22) Hwang SO, Lee TH, Bae SH, et al : Transformation of Castleman's disease into follicular dendritic cell sarcoma, presenting as an asymptomatic intra-abdominal mass. Korean J Gastroenterol 62 : 131-134, 2013
 
23) Nabel CS, Sameroff S, Shilling D, et al : Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PLoS One 14 : e0218660, 2019
 
24) Masaki Y, Nakajima A, Iwao H, et al : Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases : is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 53 : 79-85, 2013
 
25) Gherardi RK, Belec L, Fromont G, et al : Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome. Blood 83 : 2587-2593, 1994
PubMed
26) El-Osta H, Janku F, Kurzrock R : Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther 9 : 1485-1488, 2010
 
27) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
28) Fajgenbaum DC, Langan RA, Japp AS, et al : Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest 129 : 4451-4463, 2019
PubMed
29) Pierson SK, Stonestrom AJ, Shilling D, et al : Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. Am J Hematol 93 : 902-912, 2018
PubMed
30) Heinrich PC, Behrmann I, Muller-Newen G, et al : Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 (Pt 2) : 297-314, 1998
PubMed
31) Charles-Schoeman C, Burmester G, Nash P, et al : Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis 75 : 1293-1301, 2016
PubMed
32) Kawabata H, Kadowaki N, Nishikori M, et al : Clinical Features and Treatment of Multicentric Castleman's Disease : A Retrospective Study of 21 Japanese Patients at a Single Institute. J Clin Exp Hematop 53 : 69-77, 2013
 
33) Yu L, Tu M, Cortes J, et al : Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 129 : 1658-1668, 2017
PubMed
P.24 掲載の参考文献
1) 中外製薬. アクテムラ全例調査の中間報告 (キャッスルマン病) http://chugai-pharm.jp/hc/ss/pr/drug/act_via0400/report/scs/PDF/20140225_act_epmpv_safe_cd.pdf. Accessed 2016 October 5.
 
2) 吉崎和幸, 岡本真一郎, 川端浩, ほか : キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017
 
3) Dispenzieri A, Fajgenbaum DC : Overview of Castleman disease. Blood 135 : 1353-1364, 2020
PubMed
4) Munshi N, Mehra M, van de Velde H, et al : Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 56 : 1252-1260, 2015
PubMed
5) Robinson D Jr, Reynolds M, Casper C, et al : Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease : results from two US treatment centres. Br J Haematol 165 : 39-48, 2014
PubMed
6) Simpson D : Epidemiology of Castleman Disease. Hematol Oncol Clin North Am 32 : 1-10, 2018
PubMed
7) Masaki Y, Kawabata H, Fujimoto S, et al : Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan. J Clin Exp Hematop 59 : 175-178, 2019
PubMed
8) http://www.jichi.ac.jp/dph/nanbyou/manual_2017.pdf
 
P.28 掲載の参考文献
1) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
PubMed
2) Lowenthal DA, Filippa DA, Richardson ME, et al : Generalized lymphadenopathy with morphologic features of Castleman's disease in an HIV-positive man. Cancer 60 : 2454-2458, 1987
 
3) Oksenhendler E, Boutboul D, Fajgenbaum D, et al : The full spectrum of Castleman disease : 273 patients studied over 20 years. Br J Haematol 180 : 206-216, 2018
PubMed
4) Kojima M, Nakamura N, Tsukamoto N, et al : Clinical implications of idiopathic multicentric castleman disease among Japanese : a report of 28 cases. Int J Surg Pathol 16 : 391-398, 2008
PubMed
5) Kawabata H, Kadowaki N, Nishikori M, et al : Clinical Features and Treatment of Multicentric Castleman's Disease : A Retrospective Study of 21 Japanese Patients at a Single Institute. J Clin Exp Hematop 53 : 69-77, 2013
 
6) 高井和江, 新國公司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
7) Fujimoto S, Sakai T, Kawabata H, et al : Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94 : 975-983, 2019
PubMed
8) Ye B, Gao SG, Li W, et al : A retrospective study of unicentric and multicentric Castleman's disease : a report of 52 patients. Med Oncol 27 : 1171-1178, 2010
 
9) Talat N, Schulte KM : Castleman's disease : systematic analysis of 416 patients from the literature. Oncologist 16 : 1316-1324, 2011
 
10) Shin DY, Jeon YK, Hong YS, et al : Clinical dissection of multicentric Castleman disease. Leuk Lymphoma 52 : 1517-1522, 2011
PubMed
11) 中尾眞二, 日本血液学会統計調査委員会 : 我が国における血液疾患の動向 日本血液学会統計調査委員会報告. 臨床血液 54 : 2079-2085, 2013
 
12) 中外製薬 : アクテムラ全例調査の中間報告 (キャッスルマン病), 2014. http://chugai-pharm.jp/hc/ss/pr/drug/act_via0400/report/scs/PDF/20140225_act_epmpv_safe_cd.pdf
 
13) Robinson D, Jr., Reynolds M, Casper C, et al : Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease : results from two US treatment centres. Br J Haematol 165 : 39-48, 2014
PubMed
14) Munshi N, Mehra M, van de Velde H, et al : Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma 56 : 1252-1260, 2015
PubMed
15) Masaki Y, Kawabata H, Fujimoto S, et al : Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan. J Clin Exp Hematop 59 : 175-178, 2019
PubMed
16) 吉崎和幸, 岡本真一郎, 川端浩, ほか : 厚生労働科学研究費補助金 (難治性疾患等政策研究事業) キャッスルマン病の疫学診療実態調査と患者団体支援体制の構築に関する調査研究班. キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017
 
17) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : a report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
 
18) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
P.34 掲載の参考文献
1) Castleman B, Towne VW : CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises : Case 40011. N Engl J Med 250 : 26-30, 1954
 
2) Castleman B, Iverson L, Menendez VP : Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9 : 822-830, 1956
PubMed
3) Flendrig JA : Benign giant lymphoma : clinicopathologic correlation study. The Year Book of Cancer 1970 : 296-299, 1970
 
4) Keller AR, Hochholzer L, Castleman B : Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29 : 670-683, 1972
PubMed
5) Frizzera G, Banks PM, Massarelli G, et al : A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol 7 : 211-231, 1983
 
6) 森茂郎, 毛利昇, 内田俊和, ほか : 著しい多クローン性高免疫グロブリン血症と全身リンパ節の高度の形質細胞増生を呈する症候群～形質細胞型Castleman リンパ腫との異同～. 日本網内系学会会誌 20 suppl : 85-94, 1980
 
7) Lachant NA, Sun NC, Leong LA, et al : Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol 83 : 27-33, 1985
 
8) Lowenthal DA, Filippa DA, Richardson ME, et al : Generalized lymphadenopathy with morphologic features of Castleman's disease in an HIV-positive man. Cancer 60 : 2454-2458, 1987
 
9) Oksenhendler E, Duarte M, Soulier J, et al : Multicentric Castleman's disease in HIV infection : a clinical and pathological study of 20 patients. AIDS 10 : 61-67, 1996
 
10) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
11) Wang HW, Pittaluga S, Jaffe ES : Multicentric Castleman disease : Where are we now? Semin Diagn Pathol 33 : 294-306, 2016
PubMed
12) Kojima M, Nakamura S, Shimizu K, et al : Clinical implication of idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinemia : a report of 16 cases. Int J Surg Pathol 12 : 25-30, 2004
PubMed
P.45 掲載の参考文献
1) Castleman B, Towne VW : CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises : Case 40011. N Engl J Med 250 : 26-30, 1954
 
2) Fajgenbaum DC, van Rhee F, Nabel CS : HHV-8-negative, idiopathic multicentric Castleman disease : novel insights into biology, pathogenesis, and therapy. Blood 123 : 2924-2933, 2014
PubMed
3) 吉崎和幸, 岡本真一郎, 川端浩, ほか : キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017
 
4) Dong Y, Wang M, Nong L, et al : Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single center : paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol 169 : 834-842, 2015
PubMed
5) キャッスルマン病診療ガイドライン統括委員会, キャッスルマン病診療ガイドライン作成ワーキンググループ : キャッスルマン病診療ガイドライン 令和2年度初版, 2020
 
6) Kaposi M : Idiopatiches multiples pigment sarcom der Haut. Arch Dermatol Syphil 4 : 265-272, 1872
 
7) Jones JL, Hanson DL, Dworkin MS, et al : Surveillance for AIDS-Defining Opportunistic Illnesses, 1992-1997. MMWR Morb Mortal Wkly Rep 48 (SS-2) : 1-22, 1999
 
8) Chang Y, Cesarman E, Pessin MS, et al : Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266 : 1865-1869, 1994
 
9) Lachant NA, Sun NC, Leong LA, et al : Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol 83 : 27-33, 1985
 
10) Katano H, Sato Y, Kurata T, et al : Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 269 : 335-344, 2000
 
11) Soulier J, Grollet L, Oksenhendler E, et al : Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86 : 1276-1280, 1995
 
12) Aoki Y, Jaffe ES, Chang Y et al : Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93 : 4034-4043, 1999
 
13) Sullivan R, Dezube BJ, Koon HB : Signal transduction targets in Kaposi's sarcoma. Curr Opin Oncol 18 : 456-462, 2006
 
14) Dupin N, Diss TL, Kellam P, et al : HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95 : 1406-1412, 2000
PubMed
15) Hassman LM, Ellison TJ, Kedes DH : KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest 121 : 752-768, 2011
PubMed
16) Crow RS : Peripheral neuritis in myelomatosis. Br Med J 2 : 802-804, 1956
PubMed
17) 深瀬政市, 新保慎一郎, 西谷裕, ほか : 多発性神経炎および内分泌異常を惹起した孤立性骨髄腫. 日本臨床 26 : 2444-2456, 1968
Medical*Online
18) Watanabe O, Arimura K, Kitajima I, et al : Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347 : 702, 1996
PubMed
19) Nakanishi T, Sobue I, Toyokura Y, et al : The Crow-Fukase syndrome : a study of 102 cases in Japan. Neurology 34 : 712-720, 1984
PubMed
20) Dao LN, Hanson CA, Dispenzieri A, et al : Bone marrow histopathology in POEMS syndrome : a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood 117 : 6438-6444, 2011
PubMed
21) Li J, Zhou DB, Huang Z, et al : Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Ann Hematol 90 : 819-826, 2011
PubMed
22) Dispenzieri A, Kyle RA, Lacy MQ, et al : POEMS syndrome : definitions and long-term outcome. Blood 101 : 2496-2506, 2003
PubMed
23) Dispenzieri A : POEMS syndrome : 2017 update on diagnosis, risk stratification, and management. Am J Haematol 92 : 814-829, 2017
 
24) Dispenzieri A : POEMS Syndrome : 2019 Update on diagnosis, risk-stratification, and management. Am J Haematol 94 : 812-827, 2019
 
25) 高井和江, 新國公司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
26) Fajgenbaum DC, van Rhee F, Nabel CS : HHV-8-negative, idiopathic multicentric Castleman disease : novel insights into biology, pathogenesis, and therapy. Blood 123 : 2924-2933, 2014
PubMed
27) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
28) Liu AY, Nabel CS, Finkelman BS, et al : Idiopathic multicentric Castleman's disease : a systematic literature review. Lancet Haematol 3 : e163-175, 2016
 
29) Kayasut K, Le Tourneau A, Rio B, et al : Are multicentric Castleman's disease with cutaneous plasmacytosis and systemic plasmacytosis the same entity? Histopathology 49 : 557-558, 2006
 
30) Terasaki Y, Ikushima S, Matsui S, et al : Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease. Histopathology 70 : 1114-1124, 2017
 
31) Egashira R, Kondo T, Hirai T, et al : CT findings of thoracic manifestations of primary Sjogren syndrome : radiologic-pathologic correlation. Radiographics 33 : 1933-1949, 2013
PubMed
32) van Rhee F, Voorhees P, Dispenzieri A, et al : International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132 : 2115-2124, 2018
PubMed
33) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : A report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
 
34) 難病情報センター : 特発性多中心性キャッスルマン病 (https://www.nanbyou.or.jp/entry/5750)
 
35) ACCERERATE PATIENT RESEARCH STUDY (https://www.cdcn.org/accelerate)
 
P.50 掲載の参考文献
1) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
PubMed
2) Castleman B, Towne VW : CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises : Case 40011. N Engl J Med 250 : 26-30, 1954
 
3) Castleman B, Iverson L, Menendez VP : Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9 : 822-830, 1956
PubMed
4) Keller AR, Hochholzer L, Castleman B : Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29 : 670-683, 1972
PubMed
5) Bartoli E, Massarelli G, Soggia G, et al : Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol 73 : 423-426, 1980
PubMed
6) Gaba AR, Stein RS, Sweet DL, et al : Multicentric giant lymph node hyperplasia. Am J Clin Pathol 69 : 86-90, 1978
PubMed
7) Frizzera G, Banks PM, Massarelli G, et al : A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol 7 : 211-231, 1983
 
8) Crow RS : Peripheral neuritis in myelomatosis. Br Med J 2 : 802-804, 1956
PubMed
9) 深瀬政市, 新保慎一郎, 福増広幸, ほか : 多発性神経炎および内分泌異常を惹起した孤立性骨髄腫. 日本臨床 26 : 2440-2456, 1968
 
10) Takatsuki K, Sanada I : Plasma cell dyscrasia with polyneuropathy and endocrine disorder : clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol 13 : 543-555, 1983
PubMed
11) Kawabata H, Kadowaki N, Nishikori M, et al : Clinical features and treatment of multicentric Castleman's disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop 53 : 69-77, 2013
 
12) Lowenthal DA, Filippa DA, Richardson ME, et al : Generalized lymphadenopathy with morphologic features of Castleman's disease in an HIV-positive man. Cancer 60 : 2454-2458, 1987
 
13) Kojima M, Nakamura N, Tsukamoto N, et al : Clinical implications of idiopathic multicentric Castleman disease among Japanese : a report of 28 cases. Int J Surg Pathol 16 : 391-398, 2008
PubMed
14) Kurose N, Futatsuya C, Mizutani KI, et al : The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Hum Pathol 77 : 130-138, 2018
PubMed
15) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
16) 吉崎和幸, 岡本真一郎, 川端浩ほか : キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017
 
17) Yoshizaki K, Matsuda T, Nishimoto N, et al : Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74 : 1360-1367, 1989
 
18) Nishimoto N, Kishimoto T : Interleukin 6 : from bench to bedside. Nat Clin Pract Rheumatol 2 : 619-626, 2006
PubMed
19) Lachmann HJ, Goodmann HJ, Gilbertson JA : Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356 : 2361-2371, 2007
 
20) Bian AL, Hu HY, Rong YD, et al : A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-α. Eur J Med Res 22 : 25, 2017
 
21) Kawabata H, Tomosugi N, Kanda J, et al : Anti-interleukin 6 receptor antibody tocilizumab reduces the lebel of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 92 : 857-858, 2007
 
22) 友杉直久 : ヘプシジンの発見とその後の発展. 日内会誌 99 : 1180-1187, 2010
 
23) Bower M, Newsom-Davis T, Naresh K, et al : Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease. J Clin Oncol 29 : 2481-2486, 2011
 
P.56 掲載の参考文献
1) Castleman B, Iverson L, Menendez VP : Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9 : 822-830, 1956
PubMed
2) Keller AR, Hochholzer L, Castleman B : Hyaline-vascular and plasma-cell types of giant lymph node hyaperplasia of the mediastinum and other locations. Cancer 29 : 670-683, 1972
PubMed
3) Chen KT : Multicentric Castleman's disease and Kaposi's sarcoma. Am J Surg Pathol 8 : 287-293, 1984
 
4) Soulier J, Grollet L, Oksenhendler E, et al : Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86 : 1276-1280, 1995
 
5) Nicholas J, Ruvolo VR, Burns WH, et al : Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med 3 : 287-292, 1997
 
6) 木花いづみ, 石河晃, 生冨公明, ほか : 全身性形質細胞増多症. 臨皮 45 : 189-195, 1991
 
7) 中村敬哉, 佐藤公彦, 原田直子, ほか : Plasma cell interstitial pneumoniaの1例-多中心型Castleman病の肺病変として-. 日胸疾会誌 35 : 776-783, 1997
 
8) Nishimoto N, Terao K, Mima T, et al : Mechanism and pathologic significance in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112 : 3959-3964, 2008
 
9) Johkoh T, Muller NL, Ichikado K, et al : Intrathoracic multicentric Castleman disease : CT findings in 12 patients. Radiology 209 : 477-481, 1998
PubMed
10) 山洞純一, 須賀達夫, 塚越正章, ほか : Multicentiric Castleman's diseaseの胸部画像所見はリンパ節腫脹と間質性肺炎や胸水貯留である. 臨床放射線 44 : 147-152, 1999
 
11) 森貴紀, 前田佳代, 蓮沼紀一, ほか : 胸水で発見されたIdiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemiaの1例. 日呼吸会誌 38 : 288-292, 2000
Medical*Online
12) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : A report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167 : 2018
 
13) Terasaki Y, Ikushima S, Matsui S, et al : Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease. Tokyo Diffuse Lung Diseases Study Group. Histopathology 70 : 1114-1124, 2017
 
14) Weisenburger DD, Nathwani BN, Winberg CD, et al : Multicentric angiofollicular lymph node hyperplasia : a clinicopathologic study of 16 cases. Hum Pathol 16 : 162-172, 1985
PubMed
15) Frizzera G, Peterson BA, Bayrd ED, et al : A systemic lymphoproliferative disorder with morphologic features of Castleman's disease : clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3 : 1202-1216, 1985
 
16) Dupin N, Diss TL, Lellam P, et al : HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95 : 1406-1412, 2000
 
17) Yu Li, Tu M, Cortes J, et al : Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 129 : 1658-1668, 2017
PubMed
18) 吉崎和幸, 岡本真一郎, 川端浩, ほか : キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017
 
19) Nishimoto N, Kanakura Y, Aozasa K, et al : Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106 : 2627-2632, 2005
PubMed
P.59 掲載の参考文献
1) Requena L, Burg G, Cerroni L, et al : A progressive papular eruption on the chest and back. Am J Dermatopathol 26 : 162-165, 2004
 
2) Cerottini JP, Guillod J, Vion B, et al : Cutaneous plasmacytosis : an unusual presentation sharing features with POEMS syndrome? Dermatology 202 : 49-51, 2001
PubMed
3) Shimizu S, Tanaka M, Shimizu H, et al : Is cutaneous plasmacytosis a distinct clinical entity? J Am Acad Dermatol 36 : 876-880, 1997
PubMed
4) Kaneda M, Kuroda K, Fujita M, et al : Successful treatment with topical PUVA of nodular cutaneous plasmacytosis associated with alopecia of the scalp. Clin Exp Dermatol 21 : 360-364, 1996
PubMed
5) Uhara H, Saida T, Ikegawa S, et al : Primary cutaneous plasmacytosis : report of three cases and review of the literature. Dermatology 189 : 251-255, 1994
PubMed
6) Lopez-Estebaranz JL, Rodriguez-Peralto JL, Ortiz Romero PL, et al : Cutaneous plasmacytosis : report of a case in a white man. J Am Acad Dermatol 31 : 897-900, 1994
 
7) Kodama A, Tani M, Hori K, et al : Systemic and cutaneous plasmacytosis with multiple skin lesions and polyclonal hypergammaglobulinaemia : significant serum interleukin-6 levels. Br J Dermatol 127 : 49-53, 1992
PubMed
8) Watanabe S, Ohara K, Kukita A, et al : Systemic plasmacytosis. A syndrome of peculiar multiple skin eruptions, generalized lymphadenopathy, and polyclonal hypergammaglobulinemia. Arch Dermatol 122 : 1314-1320, 1986
PubMed
9) Yamamoto T, Katayama I, Nishioka K : Increased plasma interleukin-6 in cutaneous plasmacytoma : the effect of intralesional steroid therapy. Br J Dermatol 137 : 631-636, 1997
PubMed
10) Amin HM, McLaughlin P, Rutherford CJ, et al : Cutaneous and systemic plasmacytosis in a patient of Asian descent living in the United States. Am J Dermatopathol 24 : 241-245, 2002
 
11) Carey WP, Rico MJ, Nierodzik M, et al : Systemic plasmacytosis with cutaneous manifestations in a white man : successful therapy with cyclophosphamide/prednisone. J Am Acad Dermatol 38 : 629-631, 1998
 
12) Leonard AL, Meehan SA, Ramsey D, et al : Cutaneous and systemic plasmacytosis. J Am Acad Dermatol 56 : S38-40, 2007
PubMed
13) Tada Y, Komine M, Suzuki S, et al : Plasmacytosis : systemic or cutaneous, are they distinct? Acta Derm Venereol 80 : 233-235, 2000
PubMed
14) Yuri T, Yamazaki F, Takasu K, et al : Glomeruloid hemangioma. Pathology international. 58 : 390-395, 2008
PubMed
15) Caneppele S, Picart N, Bayle-Lebey P, et al : Paraneoplastic pemphigus associated with Castleman's tumour. Clin Exp Dermatol 25 : 219-221, 2000
 
16) Chorzelski T, Hashimoto T, Maciejewska B, et al : Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. J Am Acad Dermatol 41 : 393-400, 1999
PubMed
17) Kim SC, Chang SN, Lee IJ, et al : Localized mucosal involvement and severe pulmonary involvement in a young patient with paraneoplastic pemphigus associated with Castleman's tumour. Br J Dermatol 138 : 667-671, 1998
 
18) Lee IJ, Kim SC, Kim HS, et al : Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma arising from Castleman's tumor. J Am Acad Dermatol 40 : 294-297, 1999
 
19) Nikolskaia OV, Nousari CH, Anhalt GJ : Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol 149 : 1143-1151, 2003
 
20) Wang J, Zhu X, Li R, et al : Paraneoplastic pemphigus associated with Castleman tumor : a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol 141 : 1285-1293, 2005
PubMed
21) Wolff H, Kunte C, Messer G, et al : Paraneoplastic pemphigus with fatal pulmonary involvement in a woman with a mesenteric Castleman tumour. Br J Dermatol 140 : 313-316, 1999
 
22) Mimouni D, Anhalt GJ, Lazarova Z, et al : Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 147 : 725-732, 2002
PubMed
23) Sherman D, Ramsay B, Theodorou NA, et al : Reversible plane xanthoma, vasculitis, and peliosis hepatis in giant lymph node hyperplasia (Castleman's disease) : a case report and review of the cutaneous manifestations of giant lymph node hyperplasia. J Am Acad Dermatol 26 : 105-109, 1992
 
24) Yalcin AD, Keskin A, Erdogan BS, et al : Unusual case of multicentric mixed-type Castleman's disease presenting with exfoliative dermatitis. Int J Dermatol 43 : 202-205, 2004
 
25) Ashinoff R, Cohen R, Lipkin G : Castleman's tumor and erosive lichen planus : coincidence or association? Report of a case. J Am Acad Dermatol 21 : 1076-1080, 1989
 
26) Bhat L, Sams HH, King LE Jr : Bullous pemphigoid associated with Castleman disease. Arch Dermatol 137 : 965-966, 2001
PubMed
P.65 掲載の参考文献
1) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : A report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
 
2) van Rhee F, Voorhees P, Dispenzieri A, et al : International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132 : 2115-2124, 2018
PubMed
3) Zhang L, Li Z, Cao X, et al : Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease : renal function is an important prognostic factor. Sci Rep 6 : 23831, 2016
 
4) Mah NA, Peretsman SJ, Teigland CM, et al : Castleman disease of the hyaline-vascular type confined to the kidney. Am J Clin Pathol 127 : 465-468, 2007
 
5) Xu D, Lv J, Dong Y, et al : Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transplant 27 : iii119-iii125, 2012
 
6) Kojima M, Nakamura N, Tsukamoto N, et al : Clinical implications of idiopathic multicentric castleman disease among Japanese : a report of 28 cases. Int J Surg Pathol 16 : 391-398, 2008
PubMed
7) Frizzera G, Peterson BA, Bayrd ED, et al : A systemic lymphoproliferative disorder with morphologic features of Castleman's disease : clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3 : 1202-1216, 1985
 
8) Dispenzieri A, Armitage JO, Loe MJ, et al : The clinical spectrum of Castleman's disease. Am J Hematol 87 : 997-1002, 2012
 
9) El Karoui K, Vuiblet V, Dion D, et al : Renal involvement in Castleman disease. Nephrol Dial Transplant 26 : 599-609, 2011
PubMed
10) Seida A, Wada J, Morita Y, et al : Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion : does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis 43 : E3-E9, 2004
PubMed
11) Koga T, Sumiyoshi R, Kawakami A, et al : A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease. Mod Rheumatol 29 : 302-305, 2019
 
12) Komaba H, Nakazawa T, Yamaguchi Y, et al : Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease : a report of three cases. NDT Plus 1 : 423-426, 2008
 
13) Lui SL, Chan KW, Li FK, et al : Castleman's disease and mesangial proliferative glomerulonephritis : the role of interleukin-6. Nephron 78 : 323-327, 1998
 
14) Mutneja A, Cossey LN, Liapis H, et al : A rare case of renal thrombotic microangiopathy associated with Castleman's disease. BMC Nephrol 18 : 57, 2017
 
15) Wang L, Bu D, Yang Y, et al : Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 363 : 525-531, 2004
 
16) Furuichi K, Wada T, Shimizu M, et al : Antimyeloperoxidase-antibody-positive rapidly progressive glomerulonephritis associated with Castleman's disease. Nephrol Dial Transplant 13 : 1556-1558, 1998
 
17) Gu QH, Jia XY, Hu SY, et al : The Clinical and Immunologic Features of Patients With Combined Anti-GBM Disease and Castleman Disease. Am J Kidney Dis 71 : 904-908, 2018
PubMed
18) Dong Y, Wang M, Nong L, et al : Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre : paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol 169 : 834-842, 2015
PubMed
19) Zoshima T, Yamada K, Hara S, et al : Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease : Two Case Reports. Am J Surg Pathol 40 : 495-501, 2016
PubMed
20) Maeshima A, Nakasatomi M, Henmi D, et al : Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease. CEN Case Rep 1 : 7-11, 2012
 
21) Otani N, Morishita Y, Oh I, et al : Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab). Intern Med 51 : 1375-1378, 2012
 
22) Yamada Y, Ueno T, Irifuku T, et al : Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease : A case report. Clin Nephrol 90 : 232-236, 2018
 
23) Oshima Y, Hoshino J, Suwabe T, et al : Multicentric Castleman's disease associated with IgA vasculitis (Henoch-Schonlein purpura) responding well to tocilizumab : a case report. Clin Rheumatol 36 : 729-733, 2017
 
24) Ebisawa K, Masamoto Y, Tokushige J, et al : Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease. Ann Hematol 98 : 1995-1997, 2019
 
P.74 掲載の参考文献
1) Nagano Y, Kojima Y, Sawai Y : Immunite et interference dans la vaccine. Inhibiytion de l' infection dermique par le virus inactive. Comp Rend Soc Biol 148 : 750-752, 1954
 
2) Isaacs A, Lindenmann J : Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147 : 258-267, 1957
PubMed
3) Kasakura S, Lowenstein L : A factor stimulating DNA synthesis derived from the medium of leukocyte cultures. Nature 208 : 794-795,1965
PubMed
4) Yoshizaki K, Nakagawa T, Fukunaga K, et al : Characterization of human B cell growth factor (BCGF) from cloned T cells or mitogen-stimulated T cells. J Immunol 130 : 1241-1246, 1983
PubMed
5) Yoshizaki K, Nakagawa T, Fukunaga K, et al : Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line. J Immunol 132 : 2948-2954, 1984
 
6) 日本インターフェロン・サイトカイン学会編 (宇野賀津子, 米原伸, 松島綱治編) : サイトカインハンティング-先頭を駆け抜けた日本人研究者たち-. 京都市, 京都大学学術出版会, 2010
 
7) Yoshizaki K, Matsuda T, Nishimoto N, et al : Pathogenic Significance of Interleukin-6 (IL-6/BSF-2) in Castleman's Disease. Blood 74 : 1360-1367, 1989
 
8) Castleman B, Towne VW : Case records of the Massachusetts General Hospital : Case No. 40231. N Engl J Med 250 : 1001-1005, 1954
PubMed
9) Nishimoto N, Kishimoto T : Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 4 : 386-391, 2004
PubMed
10) Yoshizaki K, Nishimoto N, Mihara M, et al : Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 20 : 247-259, 1998
PubMed
11) Nakahara H, Song J, Sugimoto M, et al : Anti-Interleukin-6 Receptor Antibody Therapy Reduces Vascular Endothelial Growth Factor Production in Rheumatoid Arthritis. Arthritis Rheum 48 : 1521-1529, 2003
PubMed
P.82 掲載の参考文献
1) 吉崎和幸, 岡本真一郎, 川端浩, ほか : キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017
 
2) Cronin DM, Warnke RA : Castleman disease : an update on classification and the spectrum of associated lesions. Adv Anat Pathol 16 : 236-246, 2009
PubMed
3) Bartoli E, Massarelli G, Soggia G, et al : Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol 73 : 423-426, 1980
PubMed
4) Gaba AR, Stein RS, Sweet DL, et al : Multicentric giant lymph node hyperplasia. Am J Clin Pathol 69 : 86-90, 1978
PubMed
5) Frizzera G, Banks PM, Massarelli G, et al : A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol 7 : 211-231, 1983
 
6) 川端浩, 藤本信乃, 吉藤元, ほか : キャッスルマン病の診断と治療のガイドライン. 血液内科 82 : 394-401, 2021
 
7) Parravicini C, Corbellino M, Paulli M, et al : Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 151 : 1517-1522, 1997
 
8) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
PubMed
9) Hellgren K, Baecklund E, Backlin C, et al : Rheumatoid arthritis and risk of malignant lymphoma : Is the risk still increased? Arthritis Rhumatol 69 : 700-708, 2017
 
10) Tarella C, Gueli A, Ruella M, et al : Lymphocyte transformation and autoimmune disorders. Autoimmun Rev 12 : 802-813, 2013
PubMed
11) 正木康史, 川端浩, 高井和江, ほか : 新規疾患-TAFRO 症候群の診断基準・重症度分類・治療方針-. 臨床血液 57 : 2029-2037, 2016
 
12) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
13) Craig FE : A practical approach to the evaluation of lymphoid and plasma cell infiltrates in the lung. Surg Pathol Clin 3 : 129-154, 2010
 
14) Otani K, Inoue D, Fujikura K, et al : Idiopathic multicentric Castleman's disease : a clinicopathologic study in comparison with IgG4-related disease. Oncotarget 9 : 6691-6706, 2018
 
15) Dispenzieri A : POEMS syndrome : 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89 : 214-223, 2014
PubMed
16) Abe D, Nakaseko C, Takeuchi M, et al : Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome. Blood 112 : 836-839, 2008
PubMed
17) Frizzera G : Castleman's disease and related disorders. Semin Diagn Pathol 5 : 346-364, 1988
 
P.92 掲載の参考文献
1) Larroche C, Cacoub P, Soulier J, et al : Castleman's disease and lymphoma : report of eight cases in HIV-negative patients and literature review. Am J Hematol 69 : 119-126, 2002
 
2) Filliatre-Clement L, Busby-Venner H, Moulin C, et al : Hodgkin Lymphoma and Castleman Disease : When One Blood Disease Can Hide Another. Case Rep Hematol 2017 : 9423205, 2017
 
3) Anhalt GJ, Kim SC, Stanley JR, et al : Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 323 : 1729-1735, 1990
PubMed
4) Ahmed AR, Avram MM, Duncan LM : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 23-2003. A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N Engl J Med 349 : 382-391, 2003
PubMed
5) Kop EN, MacKenzie MA : Clinical images : Castleman disease and paraneoplastic pemphigus. CMAJ 182 : 61, 2010
PubMed
6) Camisa C, Helm TN : Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol 129 : 883-886, 1993
PubMed
7) Monda L, Warnke R, Rosai J : A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation. A report of 4 cases. Am J Pathol 122 : 562-572, 1986
PubMed
8) Chan AC, Chan KW, Chan JK, et al : Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman's disease of the nasopharynx : tracing its evolution by sequential biopsies. Histopathology 38 : 510-518, 2001
 
9) Cokelaere K, Debiec-Rychter M, De Wolf-Peeters C, et al : Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells : molecular evidence of mesenchymal tumorigenesis. Am J Surg Pathol 26 : 662-669, 2002
 
10) 今村顕史, 矢嶋敬史郎 : II カポジ肉腫 (Kaposi's sarcoma). P9-15. 平成31年度 厚生労働科学研究 エイズ対策研究事業 「エイズ患者におけるカポジ肉腫関連ヘルペスウイルスが原因となる疾患の発症機構の解明と予防および治療法に関する研究」班. AIDSに合併するカポジ肉腫等のHHV-8 関連疾患における診断と治療の手引き (第3版)
 
11) 石川哲也, 柳澤邦雄, 小川孔幸ほか : 免疫再構築症候群に対してステロイド治療が有効であった高度気道狭窄合併カポジ肉腫症例. 感染症学雑誌 91 : 25-30, 2017
 
12) Oksenhendler E, Boulanger E, Galicier L, et al : High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99 : 2331-2336, 2002
PubMed
13) Kowalkowski MA, Mims MP, Amiran ES, et al : Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PLoS One 8 : e77409, 2013
PubMed
14) Uldrick TS, Wang V, O'Mahony D, et al : An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis 51 : 350-358, 2010
 
15) Polizzotto MN, Uldrick TS, Wyvill KM, et al : Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) -associated Inflammation : Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). Clin Infect Dis 62 : 730-738, 2016
PubMed
16) Mauermann ML : Neurologic Complications of Lymphoma, Leukemia, and Paraproteinemias. Continuum (Minneap Minn) 23 (3, Neurology of Systemic Disease) : 669-690, 2017
 
17) Naddaf E, Dispenzieri A, Mandrekar J, et al : Clinical spectrum of Castleman disease-associated neuropathy. Neurology 87 : 2457-2462, 2016
PubMed
18) Li H, Huang Y, Li Y, et al : Endocrine Manifestations in POEMS Syndrome : a case report and literature review. BMC Endocr Disord 19 : 33, 2019
 
19) Hasegawa E, Sato H, Wada Y, et al : Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome. Lupus 27 : 417-427, 2018
PubMed
20) Mizuno H, Sawa N, Watanabe S, et al : The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome. Kidney Int Rep 5 : 1172-1179, 2020
PubMed
21) Kurokawa R, Gonoi W, Yokota H, et al : Computed tomography findings of early-stage TAFRO syndrome and associated adrenal abnormalities. Eur Radiol 30 : 5588-5598, 2020
PubMed
22) Murakami M, Johkoh T, Hayashi S, et al : Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan. Mod Rheumatol 30 : 843-851, 2020
PubMed
23) Lyapichev KA, You MJ, Vega F, et al : Classic Hodgkin lymphoma and Castleman disease : an entity appears to be emerging. Virchows Arch 477 : 437-444, 2020
PubMed
24) Fayand A, Boutboul D, Galicier L, et al : Epidemiology of Castleman disease associated with AA amyloidosis : description of 2 new cases and literature review. Amyloid 26 : 197-202, 2019
PubMed
25) Bernabei L, Waxman A, Caponetti G, et al : AA amyloidosis associated with Castleman disease : A case report and review of the literature. Medicine (Baltimore) 99 : e18978, 2020
PubMed
26) Kawabata H, Kadowaki N, Nishikori M, et al : Clinical features and treatment of multicentric castleman's disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop 53 : 69-77, 2013
 
27) Mandreoli M, Casanova S, Vianelli N, et al : Remission of nephrotic syndrome due to AA amyloidosis and initiation of glomerular repair after surgical resection of localized Castleman's disease. Nephron 90 : 336-340, 2002
 
28) Xu D, Lv J, Dong Y, et al : Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transplant 27 Suppl 3 : iii119-125, 2012
 
29) El Karoui K, Vuiblet V, Dion D, et al : Renal involvement in Castleman disease. Nephrol Dial Transplant 26 : 599-609, 2011
PubMed
30) Komaba H, Nakazawa T, Yamaguchi Y, et al : Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease : a report of three cases. NDT Plus 1 : 423-426, 2008
 
31) Raza HA, Nokes BT, Rosenthal AC, et al : Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus. Respir Med Case Rep 25 : 129-132, 2018
PubMed
32) Borie R, Wislez M, Antoine M, et al : Lymphoproliferative Disorders of the Lung. Respiration 94 : 157-175, 2017
PubMed
33) Aita T, Hamaguchi S, Shimotani Y, et al : Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab. BMJ Case Rep 13 : e236283, 2020
PubMed
34) Kim HJ, Han JH, Bang CH, et al : Cutaneous Disorders Associated with Castleman's Disease. Acta Derm Venereol 99 : 984-989, 2019
 
35) 奥田雅人, 大政貢, 志熊啓, ほか : 上縦隔発生の小児キャッスルマン病の1例. 日呼外会誌 23 : 213-216, 2009
 
36) Zhang J, Li C, Lv L, et al : Clinical and experimental study of Castleman disease in children. Pediatr Blood Cancer 62 : 109-114, 2015
PubMed
37) Sopfe J, Endres A, Campbell K, et al : Castleman disease in pediatrics : Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study. Pediatr Blood Cancer 66 : e27613, 2019
 
38) Kitakaze M, Miyoshi N, Fujino S, et al : Surgical resection for pelvic retroperitoneal Castleman's disease : A case report and review literature. Biomed Rep 14 : 29, 2021
 
39) Neuhof D, Debus J : Outcome and late complications of radiotherapy in patients with unicentric Castleman disease. Acta Oncol 45 : 1126-1131, 2006
PubMed
40) Rice JB, White AG, Scarpati LM, et al : Long-term Systemic Corticosteroid Exposure : A Systematic Literature Review. Clin Ther 39 : 2216-2229, 2017
PubMed
41) 川合眞一編集 : ステロイド療法のエッセンス. 月刊薬事 7月 増刊号 58 : 75-81, 2016
 
42) Sheppard M, Laskou F, Stapleton PP, et al : Tocilizumab (Actemra). Hum Vaccin Immunother 13 : 1972-1988, 2017
PubMed
43) Kaegi C, Wuest B, Schreiner J, et al : Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol 10 : 1990, 2019
PubMed
P.107 掲載の参考文献
1) Castleman B, Towne VW : CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises : Case 40011. N Engl J Med 250 : 26-30, 1954
 
2) キャッスルマン病診療ガイドライン統括委員会, キャッスルマン病診療ガイドライン作成ワーキンググループ : キャッスルマン病診療ガイドライン 令和2年度初版, 2020
 
3) Talat N, Schulte KM : Castleman's disease : systematic analysis of 416 patients from the literature. Oncologist 16 : 1316-1324, 2011
 
4) Mitsos S, Stamatopoulos A, Patrini D, et al : The role of surgical resection in Unicentric Castleman's disease : a systematic review. Adv Respir Med 86 : 36-43, 2018
 
5) Boutboul D, Fadlallah J, Chawki S, et al : Treatment and outcome of Unicentric Castleman Disease : a retrospective analysis of 71 cases. Br J Haematol 186 : 269-273, 2019
PubMed
6) Robert JH, Sgourdos G, Kritikos N, et al : Preoperative embolization of hypervascular Castleman's disease of the mediastinum. Cardiovasc Intervent Radiol 31 : 186-188, 2008
 
7) Chan KL, Lade S, Prince HM, et al : Update and new approaches in the treatment of Castleman disease. J Blood Med 7 : 145-158, 2016
PubMed
8) Gerard L, Berezne A, Galicier L, et al : Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease : ANRS 117 CastlemaB Trial. J Clin Oncol 25 : 3350-3356, 2007
 
9) 照屋勝治 : IV キャッスルマン病 (Multicentric Castleman Disease ; MCD). 平成31年度 厚生労働科学研究 エイズ対策研究事業「エイズ患者におけるカポジ肉腫関連ヘルペスウイルスが原因となる疾患の発症機構の解明と予防および治療法に関する研究」班 (研究代表者 片野晴隆). AIDSに合併するカポジ肉腫等のHHV-8関連疾患における診断と治療の手引き (第3版), pp31-36
 
10) Gerard L, Michot JM, Burcheri S, et al : Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood 119 : 2228-2233, 2012
PubMed
11) Bower M, Newsom-Davis T, Naresh K, et al : Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease. J Clin Oncol 29 : 2481-2486, 2011
 
12) Guihot A, Couderc LJ, Agbalika F, et al : Pulmonary manifestations of multicentric Castleman's disease in HIV infection : a clinical, biological and radiological study. Eur Respir J 26 : 118-125, 2005
 
13) Hoffmann C, Schmid H, Muller M, et al : Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 118 : 3499-3503, 2011
PubMed
14) Pria AD, Pinato D, Roe J, et al : Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. Blood 129 : 2143-2147, 2017
PubMed
15) Bower M, Powles T, Williams S, et al : Brief communication : rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 147 : 836-839, 2007
PubMed
16) Uldrick TS, Polizzotto MN, Aleman K, et al : Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood 124 : 3544-3552, 2014
PubMed
17) Casper C, Krantz EM, Corey L, et al : Valganciclovir for suppression of human herpesvirus-8 replication : a randomized, double-blind, placebo controlled, crossover trial. J Infect Dis 198 : 23-30, 2008
PubMed
18) 一般社団法人日本血液学会 : 造血器腫瘍診療ガイドライン 2018年度版, 東京, 金原出版 (web版 http://www.jshem.or.jp/gui-hemali/table.html)
 
19) Kourelis TV, Buadi FK, Kumar SK, et al : Long-term outcome of patients with POEMS syndrome : An update of the Mayo Clinic experience. Am J Hematol 91 : 585-589, 2016
 
20) Ohwada C, Sakaida E, Kawajiri-Manako C, et al : Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood 131 : 2173-2176, 2018
PubMed
21) Misawa S, Sato Y, Katayama K, et al : Japanese POEMS Syndrome for Thalidomide (J-POST) Trial Study Group : Safety and efficacy of thalidomide in patients with POEMS syndrome : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15 : 1129-1137, 2016
 
22) Li J, Huang XF, Cai QQ, et al : A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol 93 : 803-809, 2018
 
23) Wang X, Ye S, Xiong C, et al : Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease. Jpn J Clin Oncol 41 : 1221-1224, 2011
 
24) Sobas MA, Alonso Vence N, Diaz Arias J, et al : Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). Ann Hematol 89 : 217-219, 2010
PubMed
25) Dispenzieri A : POEMS Syndrome : 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol 94 : 812-827, 2019
PubMed
26) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
27) van Rhee F, Voorhees P, Dispenzieri A, et al : International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132 : 2115-2124, 2018
PubMed
28) Liu AY, Nabel CS, Finkelman BS, et al : Idiopathic multicentric Castleman's disease : a systematic literature review. Lancet Haematol 3 : e163-175, 2016
 
29) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : A report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
 
30) van Rhee F, Wong RS, Munshi N, et al : Siltuximab formulticentric Castleman's disease : a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15 : 966-974, 2014
 
31) Fajgenbaum DC, Langan RA, Japp AS, et al : Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest 129 : 4451-4463, 2019
PubMed
P.113 掲載の参考文献
1) Fajgenbaum DC, van Rhee F, Nabel CS : HHV-8-negative, idiopathic multicentric Castleman disease : novel insights into biology, pathogenesis, and therapy. Blood 123 : 2924-2933, 2014
PubMed
2) Talat N, Belgaumkar AP, Schulte KM : Surgery in Castleman's disease : a systematic review of 404 published cases. Ann Surg 255 : 677-684, 2012
 
3) Dispenzieri A, Armitage JO, Loe MJ, et al : The clinical spectrum of Castleman's disease. Am J Hematol 87 : 997-1002, 2012
 
4) Zhang X, Rao H, Xu X, et al : Clinical characteristics and outcomes of Castleman disease : A multicenter study of 185 Chinese patients. Cancer Sci 109 : 199-206, 2018
PubMed
5) Oksenhendler E, Boutboul D, Fajgenbaum D, et al : The full spectrum of Castleman disease : 273 patients studied over 20 years. Br J Haematol 180 : 206-216, 2018
PubMed
6) 吉崎和幸, 岡本真一郎, 川端浩, ほか : キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017
 
7) Yoshizaki K, Matsuda T, Nishimoto N, et al : Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74 : 1360-1367, 1989
 
8) Nishimoto N, Sasai M, Shima Y, et al : Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95 : 56-61, 2000
 
9) Nishimoto N, Terao K, Mima T, et al : Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112 : 3959-3964, 2008
PubMed
10) Kawabata H, Kadowaki N, Nishikori M, et al : Clinical features and treatment of multicentric Castleman's disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop 53 : 69-77, 2013
 
11) Dossier A, Meignin V, Fieschi C, et al : Human herpesvirus 8-related Castleman disease in the absence of HIV infection. Clin Infect Dis 56 : 833-842, 2013
PubMed
12) Weisenburger DD, Nathwani BN, Winberg CD, et al : Multicentric angiofollicular lymph node hyperplasia : a clinicopathologic study of 16 cases. Hum Pathol 16 : 162-172, 1985
PubMed
13) Frizzera G, Peterson BA, Bayrd ED, et al : A systemic lymphoproliferative disorder with morphologic features of Castleman's disease : clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 3 : 1202-1216, 1985
 
14) Kojima M, Nakamura N, Tsukamoto N, et al : Clinical implications of idiopathic multicentric Castleman disease among Japanese : a report of 28 cases. Int J Surg Pathol 16 : 391-398, 2008
PubMed
15) Seo S, Yoo C, Yoon DH, et al : Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease : a single medical center experience. Blood Res 49 : 253-258, 2014
 
16) Liu AY, Nabel CS, Finkelman BS, et al : Idiopathic multicentric Castleman's disease : a systematic literature review. Lancet Haematol 3 : e163-e175, 2016
 
17) Shin DY, Jeon YK, Hong YS, et al : Clinical dissection of multicentric Castleman disease. Leuk Lymphoma 52 : 1517-1522, 2011
PubMed
P.119 掲載の参考文献
1) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
2) 高井和江, 新國公司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
3) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
4) Tanaka M, Tsujimoto H, Yamamoto K, et al : Clinicopathological features of progressive renal involvement in TAFRO syndrome : A case report and literature review. Medicine 96 : e8216, 2017
PubMed
5) Kikuchi T, Shimizu T, Toyama T, et al : Successful treatment of TAFRO syndrome with tocilizumab, prednisone, and cyclophosphamide. Intern Med 56 : 2205-2211, 2017
PubMed
6) Takai K, Nikkuni K, Momoi A, et al : Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly : a clinical report of five cases. J Clin Exp Hematop 53 : 63-68, 2013
 
7) Kubokawa I, Yachie A, Hayakawa A, et al : The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman disease. BMC Pediatr 14 : 139-146, 2014
 
8) Kiguchi T, Sato C, Takai K, et al : CT findings in 11 patients with TAFRO syndrome : a variant of multicentric Castleman's disease. Clin Radiol 72 : 905.e1-905.e5, 2017
 
9) Yamaga Y, Tokuyama K, Kato T, et al : Successful treatment with cyclosporine A in tocilizumab-resistant TAFRO syndrome. Intern Med 55 : 185-190, 2016
PubMed
10) Shirai T, Onishi A, Waki D, et al : Successful treatment with tacrolimus in TAFRO syndrome : two case reports and literature review. Medicine 97 : e11045, 2018
PubMed
11) Tsurumi H, Fujigaki Y, Yamamoto T, et al : Remission of refractory ascites and discontinuation of hemodialysis after additional rituximab to long-term glucocorticoid therapy in a patient with TAFRO syndrome. Intern Med 57 : 1433-1438, 2018
 
12) Hiramatsu S, Ohmura K, Tsuji H, et al : Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Jpn J Clin Immunol 39 : 64-71, 2016
 
13) Fujiki T, Hirasawa S, Watanabe S, et al : Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome. CEN Case Rep 6 : 105-110, 2017
 
14) Fujiwara S, Mochinaga H, Nakata H, et al : Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol 103 : 718-723, 2016
PubMed
15) Takayama Y, Kubota T, Ogino Y, et al : TAFRO syndrome with disseninated intravascular coagulation successfully treated with tocilizumab and recombinant thrombomodulin. Intern Med 57 : 1291-1296, 2018
PubMed
16) Kojima M, Nakamura N, Tsukamoto N, et al : Clinical implications of idiopathic multicentric Castleman disease among Japanese. A report of 28 cases. Int J Surg Pathol 16 : 391-398, 2008
PubMed
17) Kurose N, Futatsuya C, Mizutani KI, et al : The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Hum Pathol 77 : 130-138, 2018
PubMed
18) Takai K : TAFRO syndrome : A novel systemic inflammatory disorder characterized by thrombocytopenia, anasarca, fever, renal dysfunction and organomegaly. J Blood Lymph 7 : 172, 2017
 
19) 正木康史, 藤本信乃, 黒瀬望, ほか : TAFRO症候群. 血液内科 77 : 79-85, 2018
 
20) Iwaki N, Gion Y, Kondo E, et al : Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep 7 : 42316, 2017
 
P.125 掲載の参考文献
1) Umehara H, Okazaki K, Masaki Y, et al : Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22 : 21-30, 2012
PubMed
2) Stone JH, Zen Y, Deshpande V : IgG4-related disease. N Engl J Med 366 : 539-551, 2012
PubMed
3) Kamisawa T, Zen Y, Pillai S, et al : IgG4-related disease. Lancet 385 : 1460-1471, 2015
PubMed
4) Inoue D, Yoshida K, Yoneda N, et al : IgG4-related disease : dataset of 235 consecutive patients. Medicine (Baltimore) 94 : e680, 2015
PubMed
5) Yamada K, Yamamoto M, Saeki T, et al : New clues to the nature of immunoglobulin G4-related disease : a retrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther 19 : 262, 2017
 
6) Cheuk W, Chan JK : Lymphadenopathy of IgG4-related disease : an underdiagnosed and overdiagnosed entity. Semin Diagn Pathol 29 : 226-234, 2012
PubMed
7) Deshpande V, Zen Y, Chan JK, et al : Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25 : 1181-1192, 2012
PubMed
8) Sato Y, Kojima M, Takata K, et al : Systemic IgG4-related lymphadenopathy : a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol 22 : 589-599, 2009
 
9) Sato Y, Yoshino T : IgG4-related lymphadenopathy. Int J Rheumatol 2012 : 572539, 2012
PubMed
10) Sato Y, Kojima M, Takata K, et al : Multicentric Castleman's disease with abundant IgG4-positive cells : a clinical and pathological analysis of 6 cases. J Clin Pathol 63 : 1084-1089, 2010
 
11) Sasaki T, Akiyama M, Kaneko Y, et al : Distinct features distinguishing IgG4-related disease from multicentric Castleman's disease. RMD Open 3 : e000432, 2017
 
12) 佐藤康晴, 吉野正 : リンパ節病変. IgG4関連疾患アトラス, 川茂幸, 川野充弘編集, 金沢, 前田書店, 2012, pp165-172
 
13) Zoshima T, Yamada K, Hara S, et al : Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease : Two Case Reports. Am J Surg Pathol 40 : 495-501, 2016
PubMed
14) Takeuchi M, Sato Y, Takata K, et al : Cutaneous multicentric Castleman's disease mimicking IgG4-related disease. Pathol Res Pract 208 : 746-749, 2012
 
15) Terasaki Y, Ikushima S, Matsui S, et al : Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease. Histopathology 70 : 1114-1124, 2017
 
16) 川野充弘, 全陽, 井上大, ほか : CASE 12 多クローン性高ガンマグロブリン血症を伴う特発性形質細胞性リンパ節症 (IPL) の1例. よくわかるIgG4関連疾患, 川野充弘ほか編集, 東京, 中外医学社, 2017, pp163-175
 
17) 川野充弘, 全陽, 井上大, ほか : CASE 13 間歇熱と体重減少, 全身倦怠感にて発症し後腹膜線維症による水腎症を併発した多中心性キャッスルマン病の1例. よくわかるIgG4関連疾患, 川野充弘ほか編集, 東京, 中外医学社, 2017, pp176-185
 
18) 川野充弘, 全陽, 井上大, ほか : CASE 11 腎盂病変や腎周囲の後腹膜病変, 腎実質病変を伴った多中心性キャッスルマン病の1例. よくわかるIgG4 関連疾患, 川野充弘ほか編集, 東京, 中外医学社, 2017, pp153-162
 
19) 川野充弘, 全陽, 井上大, ほか : CASE 10 原因不明の高IgG 血症, 高IgG4血症で経過観察中にリンパ節病変と腎機能低下が出現した多中心性キャッスルマン病の1例. よくわかるIgG4 関連疾患, 川野充弘ほか編集, 東京, 中外医学社, 2017, pp142-152
 
P.132 掲載の参考文献
1) Crow RS : Peripheral neuritis in myelomatosis. Br Med J 2 : 802-804, 1956
PubMed
2) Suichi T, Misawa S, Beppu M, et al : Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology 93 : e975-e983, 2019
PubMed
3) Soubrier MJ, Dubost JJ, Sauvezie BJ : POEMS syndrome : a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med 97 : 543-553, 1994
 
4) Nakanishi T, Sobue I, Toyokura Y, et al : The Crow-Fukase syndrome : a study of 102 cases in Japan. Neurology 34 : 712-720, 1984
PubMed
5) Dispenzieri A : POEMS Syndrome : 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol 94 : 812-827, 2019
PubMed
6) Watanabe O, Arimura K, Kitajima I, et al : Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347 : 702, 1996
PubMed
7) Hashiguchi T, Arimura K, Matsumuro K, et al : Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. Muscle Nerve 23 : 1051-1056, 2000
PubMed
8) Misawa S, Sato Y, Katayama K, et al : Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response : retrospective cohort study. BMJ Open 5 : e009157, 2015
PubMed
9) Abe D, Nakaseko C, Takeuchi M, et al : Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome. Blood 112 : 836-839, 2008
PubMed
10) Kawajiri-Manako C, Mimura N, Fukuyo M, et al : Clonal immunoglobulin lambda light-chain gene rearrangements detected by next generation sequencing in POEMS syndrome. Am J Hematol 93 : 1161-1168, 2018
PubMed
11) Nagao Y, Mimura N, Takeda J, et al : Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia 33 : 1723-1735, 2019
PubMed
12) Dispenzieri A, Kyle RA, Lacy MQ, et al : POEMS syndrome : definitions and long-term outcome. Blood 101 : 2496-2506, 2003
PubMed
13) Dao LN, Hanson CA, Dispenzieri A, et al : Bone marrow histopathology in POEMS syndrome : a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood 117 : 6438-6444, 2011
PubMed
14) Li J, Zhou DB, Huang Z, et al : Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Ann Hematol 90 : 819-826, 2011
PubMed
15) Wang X, Ye S, Xiong C, et al : Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease. Jpn J Clin Oncol 41 : 1221-1224, 2011
 
16) Belec L, Mohamed AS, Authier FJ, et al : Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood 93 : 3643-3653, 1999
 
17) Dao LN, Hanson CA, Dispenzieri A, et al : Bone marrow histopathology in POEMS syndrome : a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood 117 : 6438-6444, 2011
PubMed
18) Misawa S, Sato Y, Katayama K, et al : Safety and efficacy of thalidomide in patients with POEMS syndrome : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15 : 1129-1137, 2016
PubMed
19) Royer B, Merlusca L, Abraham J, et al : Efficacy of lenalidomide in POEMS syndrome : a retrospective study of 20 patients. Am J Hematol 88 : 207-212, 2013
PubMed
20) Kourelis TV, Buadi FK, Kumar SK, et al : Long-term outcome of patients with POEMS syndrome : An update of the Mayo Clinic experience. Am J Hematol 91 : 585-589, 2016
 
21) Ohwada C, Sakaida E, Kawajiri-Manako C, et al : Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood 131 : 2173-2176, 2018
PubMed
22) Sobas MA, Alonso Vence N, Diaz Arias J, et al : Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). Ann Hematol 89 : 217-219, 2010
PubMed
23) Ganti AK, Pipinos I, Culcea E, et al : Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. Am J Hematol 79 : 206-210, 2005
PubMed
P.141 掲載の参考文献
1) Fujimoto S, Sakai T, Kawabata H, et al : Osteosarcoma Manifesting Systemic Inflammation and Histological Features Mimicking Plasma Cell-type Castleman Disease. Intern Med 58 : 2555-2560, 2019
PubMed
2) Frizzera G : Castleman's disease and related disorders. Semin Diagn Pathol 5 : 346-364, 1988
 
3) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
PubMed
4) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : a report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
 
5) van Rhee F, Voorhees P, Dispenzieri A, et al : International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132 : 2115-2124, 2018
PubMed
6) Jain P, Prieto VG, Manning JT, et al : Synchronous presentation of intra-nodal follicular dendritic cell sarcoma and Castleman disease. Am J Hematol 92 : 478-479, 2017
PubMed
7) Katano H, Kaneko K, Shimizu S, et al : Follicular dendritic cell sarcoma complicated by hyaline-vascular type Castleman's disease in a schizophrenic patient. Pathol Int 47 : 703-706, 1997
 
8) Kakiuchi C, Ishida T, Sato H, et al : Secretion of interleukin-6 and vascular endothelial growth factor by spindle cell sarcoma complicating Castleman's disease (so-called 'vascular neoplasia'). J Pathol 197 : 264-271, 2002
 
9) Kraus MD, Guillou L, Fletcher CD : Well-differentiated inflammatory liposarcoma : an uncommon and easily overlooked variant of a common sarcoma. Am J Surg Pathol 21 : 518-527, 1997
PubMed
10) Dong Y, Liu B, Ju G, et al : Concomitant perinephric Castleman disease and renal cell carcinoma initially suspected to be metastasis : A case report and 24 months follow up. Urol Case Rep 22 : 70-72, 2018
PubMed
11) Chen S, Song L, Xie X, et al : A case of abdominal mesenteric Castleman's disease with left renal cell carcinoma and stomach leiomyoma. Hell J Nucl Med 19 : 285-288, 2016
 
12) Kremer A, Kremer V, Lee SK : Spontaneous kidney rupture with incidental renal cell cancer in patient with Castleman's disease. Urology 74 : 787-788, 2009
 
13) Chan JJ, Loh AH, Sim HG, et al : Coexistence of unicentric Castleman's Disease and locally advanced papillary renal cell carcinoma : More than a coincidental association? Ann Acad Med Singap 39 : 584-585, 2010
 
14) Fujimoto S, Kawabata H, Kurose N, et al : Sjogren's syndrome manifesting as clinicopathological features of TAFRO syndrome. A case report. Medicine (Baltimore) 96 : e9220, 2017
 
15) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
16) Iwanaga N, Harada K, Tsuji Y, et al : TAFRO syndrome with primary Sjogren's syndrome. Nihon Rinsho Meneki Gakkai Kaishi 39 : 478-484, 2016
 
17) Koo CH, Nathwani BN, Winberg CD, et al : Atypical lymphoplasmacytic and immunoblastic proliferation in lymph nodes of patients with autoimmune disease (autoimmune-disease-associated lymphadenopathy). Medicine 63 : 274-290, 1984
PubMed

第2章 TAFRO症候群

P.149 掲載の参考文献
1) 高井和江, 新國公司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
2) 正木康史, 川端浩, 高井和江, ほか : 新規疾患-TAFRO 症候群の診断基準・重症度分類・治療指針-. 臨床血液 57 : 2029-2037, 2016
 
3) Masaki Y, Kawabata H, Takai K, et al : 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 111 : 155-158, 2020
PubMed
4) Kawabata H, Kadowaki N, Nishikori M, et al : Clinical features and treatment of multicentric castleman's disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop 53 : 69-77, 2013
 
5) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2018
 
6) Kawabata H, Takai K, Kojima M, et al : Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53 : 57-61, 2013
 
7) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : A report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
 
8) Fajgenbaum DC : Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood 132 : 2323-2330, 2018
PubMed
9) Srkalovic G, Marijanovic I, Srkalovic MB, et al : TAFRO syndrome : New subtype of idiopathic multicentric Castleman disease. Bosn J Basic Med Sci 17 : 81-84, 2017
PubMed
10) Takai K : TAFRO Syndrome : A Novel Systemic Inflammatory Disorder Characterized by Thrombocytopenia, Anasarca, Fever, Renal Dysfunction and Organomegaly. J Blood Lymph 7 : 173, 2017
 
11) Fujimoto S, Kawabata H, Kurose N, et al : Sjogren's syndrome manifesting as clinicopathological features of TAFRO syndrome : A case report. Medicine (Baltimore) 96 : e9220, 2017
 
12) Hasegawa E, Sato H, Wada Y, et al : Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome. Lupus 27 : 417-427, 2018
PubMed
13) 青木定夫 : TAFRO症候群の病態と治療. 血液内科 70 : 223-228, 2015
 
14) Suichi T, Misawa S, Sato Y, et al : Proposal of new clinical diagnostic criteria for POEMS syndrome. J Neurol Neurosurg Psychiatry 90 : 133-137, 2019
PubMed
15) Kurose N, Futatsuya C, Mizutani KI, et al : The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Hum Pathol 77 : 130-138, 2018
PubMed
16) Fujimoto S, Sakai T, Kawabata H, et al : Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94 : 975-983, 2019
PubMed
17) Uchiyama T, Yokoyama A, Aoki S : Differences in the pathophysiological features of TAFRO syndrome in the presence or absence of lymphadenopathy. The 1st International Symposium on Castleman Disease. abst Sept., 2021
 
18) Mizuno H, Sekine A, Oguro M, et al : Renal histology in a patient with TAFRO syndrome : a case report. Hum Pathol 82 : 258-263, 2018
 
19) Kurose N, Mizutani KI, Kumagai M, et al : An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Pathol Res Pract 215 : 410-413, 2019
PubMed
P.154 掲載の参考文献
1) Nagy A, Bhaduri A, Shahmarvand N, et al : Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. Blood Adv 2 : 481-491, 2018
PubMed
2) コハネ, ビュート, コー, ほか : 統合ゲノミクスのためのマイクロアレイ データアナリシス, シュプリンガー・ジャパン, 2004
 
3) 鈴木譲 : NGSアプリケーション. RNA-Seq実験ハンドブック, 東京, 羊土社, 2016
 
4) Nakajima A, Masaki Y, Nakamura T, et al : Decreased expression of innate immunity-related genes in peripheral blood mononuclear cells from patients with IgG4-related disease. PLoS ONE 10 : e0126582, 2015
PubMed
5) Chang YC, Su CY, Chen MH, et al : Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis. Mol Cancer 16 : 135, 2017
PubMed
6) Nakajima H, Koizumi K, Tanaka T, et al : Loss of HITS (FAM107B) expression in cancers of multiple organs : tissue microarray analysis. Int J Oncol 41 : 1347-1357, 2012
PubMed
7) 荒木啓充, HURLEY Daniel, CRAMPIN Edmund, ほか : 遺伝子ネットワーク解析とその応用. 生物物理 51 : 182-185, 2011
Medical*Online
8) Tsuboi H, Nakai Y, Iizuka M, et al : DNA microarray analysis of labial salivary glands in IgG4-related disease : comparison with Sjogren's syndrome. Arthritis Rheumatol 66 : 2892-2899, 2014
 
9) Magagula L, Gagliardi M, Naidoo J, et al : Lnc-ing inflammation to disease. Biochem Soc Trans 45 : 953-962, 2017
PubMed
10) Marques-Rocha JL, Samblas M, Milagro FI, et al : Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J 29 : 3595-3611, 2015
PubMed
11) Fang Y, Wang X, Li W, et al : Screening of circular RNAs and validation of circANKRD36 assiciated with inflammation in patients with type 2 diabetes mellitus. Int J Mol Med 42 : 1865-1874, 2018
 
12) Fujita Y, Kosaka N, Araya J, et al : Extracellular vesicles in lung microenvironment and pathogenesis. Trends Mol Med 21 : 533-542, 2015
PubMed
13) Nakai W, Yoshida T, Diez D, et al : A novel affinity-based method for the isolation of highly purified extraxcellular vesicles. Sci Rep 6 : 33935, 2016
 
14) Vaught J : Biobanking comes of age : The transition to biospecimen science. Annu Rev Pharmacol Toxicol 56 : 211-228, 2016
PubMed
P.159 掲載の参考文献
1) Castleman B, Iverson L, Menendez VP : Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9 : 822-830, 1956
PubMed
2) Keller AR, Hochholzer L, Castleman B : Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29 : 670-683, 1972
PubMed
3) Waterston A, Bower M : Fifty years of multicentric Castleman's disease. Acta Oncol 43 : 698-704, 2004
 
4) Kawabata H, Kadowaki N, Nishikori M, et al : Clinical features and treatment of multicentric Castleman's disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop 53 : 69-77, 2013
 
5) 小島勝 : Castleman病診断の進歩. 病理と臨床 35 : 545-548, 2017
Medical*Online
6) Mylona EE, Baraboutis IG, Lekakis LJ, et al : Multicentric Castleman's disease in HIV infection : a systematic review of the literature. AIDS Rev 10 : 25-35, 2008
 
7) Kojima M, Nakamura S, Nishikawa M, et al : Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohistochemical study of five cases. Pathol Res Pract 201 : 325-332, 2005
 
8) Kojima M, Nakamura N, Tsukamoto N, et al : Clinical implications of idiopathic multicentric castleman disease among Japanese : a report of 28 cases. Int J Surg Pathol 16 : 391-398, 2008
PubMed
9) 高井和江, 新國広司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
10) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
11) Fajgenbaum DC, van Rhee F, Nabel CS : HHV-8-negative, idiopathic multicentric Castleman disease : novel insights into biology, pathogenesis, and therapy. Blood 123 : 2924-2933, 2014
PubMed
12) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International, evidence based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
PubMed
13) Kurose N, Futatsuya C, Mizutani KI, et al : The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Hum Pathol 77 : 130-138, 2018
PubMed
14) 森茂郎, 毛利昇, 内田俊和, ほか : 著しい多クローン性高免疫グロブリン血症と全身リンパ節の高度の形質細胞増生を呈する症候群 : 形質細胞型Castlemanリンパ腫との異同. 日網内系学会会誌 20 suppl : 85-94, 1980
 
P.163 掲載の参考文献
1) Takai K, Nikkuni K, Momoi A, et al : Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly : a clinical report of five cases. J Clin Exp Hematop 53 : 63-68, 2013
 
2) Kubokawa I, Yachie A, Hayakawa A, et al : The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman disease. BMC Pediatr 14 : 139-146, 2014
 
3) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
4) Louis C, Vijgen S, Samii K, et al : TAFRO syndrome in Caucasians : a case report and review of the literature. Front Med 4 : 149, 2017
PubMed
5) Owattanapanich W, Pholmoo W, Pongpruttipan T, et al : High proportion of TAFRO syndrome in Thai adult Castleman's disease patients : a 10-year experience. Ann Hematol 97 : 1019-1026, 2018
 
6) Kiguchi T, Sato C, Takai K, et al : CT findings in 11 patients with TAFRO syndrome : a variant of multicentric Castleman's disease. Clin Radiol 72 : 905.e1-905.e5, 2017
 
7) Furuto Y, Hashimoto H, Horiuti H, et al : Membranoproliferative glomerulonephritis-like findings for TAFRO syndrome, associated with an anterior mediastinal tumor : a case report. Medicine 97 : e11057, 2018
PubMed
8) Kawabata H, Takai K, Kojima M, et al : Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53 : 57-61, 2013
 
9) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
10) Kurose N, Futatsuya C, Mizutani KI, et al : The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Hum Pathol 77 : 130-138, 2018
PubMed
11) Tanaka M, Tsujimoto H, Yamamoto K, et al : Clinicopathological features of progressive renal involvement in TAFRO syndrome : a case report and literature review. Medicine 96 : e8216, 2017
PubMed
12) Kikuchi T, Shimizu T, Toyama T, et al : Successful treatment of TAFRO syndrome with tocilizumab, prednisone, and cyclophosphamide. Intern Med 56 : 2205-2211, 2017
PubMed
13) Tsurumi H, Fujigaki Y, Yamamoto T, et al : Remission of refractory ascites and discontinuation of hemodialysis after additional rituximab to long-term glucocorticoid therapy in a patient with TAFRO syndrome. Intern Med 57 : 1433-1438, 2018
 
14) Hiramatsu S, Ohmura K, Tsuji H, et al : Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Jpn J Clin Immunol 39 : 64-71, 2016
 
15) Yasuda S, Tanaka K, Ichikawa A, et al : Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy. Int J Hematol 104 : 512-518, 2016
PubMed
16) Shirai T, Onishi A, Waki D, et al : Successful treatment with tacrolimus in TAFRO syndrome : two case reports and literature review. Medicine 97 : e11045, 2018
PubMed
17) Fujiwara S, Mochinaga H, Nakata H, et al : Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy with anti-IL-6 receptor antibody and steroids. Int J Hematol 103 : 718-723, 2016
PubMed
18) Fujiki T, Hirasawa S, Watanabe S, et al : Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome. CEN Case Rep 6 : 105-110, 2017
 
19) Yamaga Y, Tokuyama K, Kato T, et al : Successful treatment with cyclosporine A in toilizumab-resistant TAFRO syndrome. Intern Med 55 : 185-190, 2016
PubMed
20) Meguri Y, Asada N, Nakasako Y, et al : A case report of TAFRO syndrome successfully treated by immunosuppressive therapies with plasma exchange. Ann Hematol 98 : 537-539, 2019
PubMed
21) 鈴木一正, 中村海人, 粕谷忠道, ほか : シクロフォスファミド大量静注療法が著効を示したTAFRO症候群の1例. 日内会誌 105 : 2417-2425, 2016
 
22) Tatekawa S, Umemura K, Fukuyama R, et al : Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep 3 : 472-478, 2015
PubMed
23) Fujimoto S, Kawabata H, Masaki Y, et al : Seeking optimal treatment for TAFRO syndrome : a retrospective study from a multicenter registry. Jpn J Clin Hematol 59 : 1490, 2018
 
24) Kawashima M, Usui T, Okada H, et al : TAFRO syndrome : 2 cases and review of the literature. Mod Rheumatol 27 : 1093-1097, 2017
PubMed
P.167 掲載の参考文献
1) 高井和江, 新國公司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
2) Kawabata H, Takai K, Kojima M, et al : Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 53 : 57-61, 2013
 
3) 正木康史, 川端浩, 高井和江, ほか : 新規疾患-TAFRO症候群の診断基準・重症度分類・治療指針-. 臨床血液 57 : 2029-2037, 2016
 
4) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
5) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
6) Masaki Y, Nakajima A, Iwao H, et al : Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases : is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 53 : 79-85, 2013
 
7) Coutier F, Meaux Ruault N, Crepin T, et al : A comparison of TAFRO syndrome between Japanese and non-Japanese cases : a case report and literature review. Ann Hematol 97 : 401-407, 2018
 
8) Kojima M, Nakamura N, Tsukamoto N, et al : Clinical implications of idiopathic multicentric castleman disease among Japanese : a report of 28 cases. Int J Surg Pathol 16 : 391-398, 2008
PubMed
9) Liu AY, Nabel CS, Finkelman BS, et al : Idiopathic multicentric Castleman's disease : a systematic literature review. Lancet Haematol 3 : e163-175, 2016
 
P.170 掲載の参考文献
1) 高井和江, 新國広司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
2) Kurose N, Mizutani KI, Kumagai M, et al : An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Pathol Res Pract 215 : 410-413, 2019
PubMed
3) Thiele J, Kvasnicka HM : Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol 32 : 380-394, 2005
PubMed
4) 宮内潤 : 巨核球の形態異常をきたす骨髄性腫瘍の鑑別. 腫瘍病理鑑別診断アトラス 造血器腫瘍, 定平吉都他編, 第1版, 東京, 文光堂, 2013, pp208-213
 
5) 茅野秀一, 荒関かやの : 骨髄線維化をきたす骨髄の鑑別. 腫瘍病理鑑別診断アトラス造血器腫瘍, 定平吉都他編, 第1版, 東京, 文光堂, 2013, pp203-207
 
6) Rameshwar P, Joshi DD, Yadav P, et al : Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fibrosis. Blood 97 : 3025-3031, 2001
PubMed
7) 岩城憲子 : 新しい疾患概念 [2] TAFRO症候群. 病理と臨床 35 : 540-544, 2017
Medical*Online
8) Foucar K, Viswanatha DS, Wilson CS : Non-neoplastic disorders of bone marrow, Donald WK, 1st edition, Washington, DC, AFIP, 2008, pp274-277
 
P.175 掲載の参考文献
1) Kiguchi T, Sato C, Takai K, et al : CT findings in 11 patients with TAFRO syndrome : a variant of multicentric Castleman's disease. Clin Radiol 72 : 905.e1-905.e5, 2017
 
2) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
3) Ozawa Y, Yamamoto H, Yasuo M, et al : Two patients with TAFRO syndrome exhibiting strikingly similar anterior mediastinal lesions with predominantly fat attenuation on chest computed tomography. Respir Investig 55 : 176-180, 2017
PubMed
4) Light RW, Macgregor MI, Luchsinger PC, et al : Pleural effusions : the diagnostic separation of transudates and exudates. Ann Intern Med 77 : 507-513, 1972
PubMed
5) 橋口照人 : むくみとVEGF. 綜合臨牀 55 : 2611-2614, 2006
Medical*Online
6) Kimura K, Hashiguchi T, Deguchi T, et al : Serum VEGF--as a prognostic factor of atherosclerosis. Atherosclerosis 194 : 182-188, 2007
PubMed
7) Masaki Y, Nakajima A, Iwao H, et al : Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases : is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 53 : 79-85, 2013
 
8) 正木康史, 清水啓智, 中村 (佐藤) 智美, ほか : TAFRO症候群. 日本臨牀 73 (増刊号 8) : 674-678, 2015
 
9) Sakashita K, Murata K, Inagaki Y, et al : An anterior mediastinal lesion in TAFRO syndrome showing complete remission after glucocorticoid and tocilizumab therapy. Respirol Case Rep 4 : e00173, 2016
PubMed
10) Furuto Y, Hashimoto H, Horiuti H, et al : Membranoproliferative glomerulonephritis-like findings for TAFRO syndrome, associated with an anterior mediastinal tumor : A case report. Medicine (Baltimore) 97 : e11057, 2018
PubMed
11) Lee SY, Lee J, Lee HJ, et al : Anterior mediastinal fat in Behcet's disease : qualitative and quantitative CT analysis. Int J Cardiovasc Imaging 29 Suppl 2 : 119-126, 2013
PubMed
12) Johkoh T, Muller NL, Ichikado K, et al : Intrathoracic multicentric Castleman disease : CT findings in 12 patients. Radiology 209 : 477-481, 1998
PubMed
13) Nishimoto N, Honda O, Sumikawa H, et al : A Long-Term (5-Year) Sustained Efficacy of Tocilizumab for Multicentric Castleman's Disease and the Effect on Pulmonary Complications. Blood 110 : 646, 2007
 
P.176 掲載の参考文献
1) Nakamura Y, Iwamoto K, Fujisawa Y, et al : Multiple haemangiomas in TAFRO syndrome with atypical features of glomeruloid and epithelioid haemangiomas. Eur J Dermatol 28 : 371-372, 2018
PubMed
2) Shinozaki-Ushiku A, Higashihara T, Ikemura M, et al : Glomeruloid hemangioma associated with TAFRO syndrome. Hum Pathol 82 : 172-176, 2018
PubMed
P.178 掲載の参考文献
1) Noda-Narita S, Sumida K, Sekine A, et al : TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim : a case report. CEN Case Rep 7 : 162-168, 2018
PubMed
2) Mizuno H, Sekine A, Oguro M, et al : Renal histology in a patient with TAFRO syndrome : a case report. Hum Pathol 82 : 258-263, 2018
 
3) Mizuno H, Sawa N, Watanabe S, et al : The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome. Kidney Int Rep 5 : 1172-1179, 2020
PubMed
P.181 掲載の参考文献
1) Iwaki N, Gion Y, Kondo E, et al : Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep 7 : 42316, 2017
 
2) Antonelli A, Ferrari SM, Giuggioli D, et al : Chemokine (C-X-C motif) ligand (CXCL) 10 in autoimmune disease. Autoimmun Rev 13 : 272-280, 2014
 
3) 今堀和友, 山川民夫監修 : 生化学辞典 第4版, 東京, 東京化学同人, 2007
 
4) Pierson SK, Stonestrom AJ, Shilling D, et al : Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. Am J Hematol 93 : 902-912, 2018
PubMed
5) Klitmatcheva E, Pandina T, Reilly C, et al : CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol 16 : 6, 2015
 
6) 佐賀智之, 石原敏道, 金川実千代, ほか : 幼若血小板比率の継時的測定が臨床上有用であったTAFRO症候群. 臨床血液 59 : 991-996, 2018
 
P.187 掲載の参考文献
1) 高井和江, 新國公司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
2) Masaki Y, Nakajima A, Iwao H, et al : Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases : is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 53 : 79-85, 2013
 
3) Takai K, Nikkuni K, Momoi A, et al : Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly : a clinical report of five cases. J Clin Exp Hematop 53 : 63-68, 2013
 
4) Kawabata H, Kadowaki N, Nishikori M, et al : Clinical Features and Treatment of Multicentric Castleman's Disease : A Retrospective Study of 21 Japanese Patients at a Single Institute. J Clin Exp Hematop 53 : 69-77, 2013
 
5) Iwaki N, Sato Y, Takata K, et al : Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop 53 : 87-93, 2013
 
6) Kawabata H, Takai K, Kojima M, et al : Castleman-Kojima Disease (TAFRO Syndrome) : A Novel Systemic Inflammatory Disease Characterized by a Constellation of Symptoms, Namely, Thrombocytopenia, Ascites (Anasarca), Microcytic Anemia, Myelofibrosis, Renal Dysfunction, and Organomegaly : A Status Report and Summary of Fukushima (6 June, 2012) and Nagoya Meetings (22 September, 2012). J Clin Exp Hematop 53 : 57-61, 2013
 
7) Kojima M, Nakamura N, Tsukamoto N, et al : Clinical Implications of Idiopathic Multicentric Castleman Disease Among Japanese : A Report of 28 Cases. Int J Surg Pathol 16 : 391-398, 2008
PubMed
8) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
9) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
10) 正木康史, 川端浩, 高井和江, ほか : 新規疾患-TAFRO症候群の診断基準・重症度分類・治療指針-. 臨床血液 57 : 2029-2037, 2016
 
11) Masaki Y, Kawabata H, Takai K, et al : 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 111 : 155-158, 2020
PubMed
12) 佐藤康晴 : Castleman-Kojima diseaseとTAFRO症候群. 病理と臨床 37 : 899-901, 2019
Medical*Online
13) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
PubMed
14) Fujimoto S, Sakai T, Kawabata H, et al : Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol 94 : 975-983, 2019
PubMed
15) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : A report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
 
16) Carbone A, Pantanowitz L : TAFRO syndrome : An atypical variant of KSHV-negative multicentric Castleman disease. Am J Hematol 91 : 171-172, 2016
PubMed
17) Kurose N, Futatsuya C, Mizutani K, et al : The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Hum Pathol 77 : 130-138, 2018
PubMed
P.193 掲載の参考文献
1) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
2) Fujimoto S, Kawabata H, Kurose N, et al : Sjogren's syndrome manifesting as clinicopathological features of TAFRO syndrome : A case report. Medicine (Baltimore) 96 : e9220, 2017
 
3) 岩永希, 原田康平, 辻良香, ほか : TAFRO 症候群類似の臨床像を呈した原発性シェーグレン症候群の1例. 日本臨床免疫学会会誌 39 : 478-484, 2016
Medical*Online
4) Ohya E, Mizutani M, Sakaguchi H, et al : Diffuse Large B-cell Lymphoma during Corticosteroid Therapy for TAFRO Syndrome. Intern Med 55 : 2861-2867, 2016
PubMed
5) Shinozaki-Ushiku A, Higashihara T, Ikemura M, et al : Glomeruloid hemangioma associated with TAFRO syndrome. Hum Pathol 82 : 172-176, 2018
PubMed
6) Sakashita K, Murata K, Inagaki Y, et al : An anterior mediastinal lesion in TAFRO syndrome showing complete remission after glucocorticoid and tocilizumab therapy. Respirol Case Rep 4 : e00173, 2016
PubMed
7) Furuto Y, Hashimoto H, Horiuti H, et al : Membranoproliferative glomerulonephritis-like findings for TAFRO syndrome, associated with an anterior mediastinal tumor : A case report. Medicine (Baltimore) 97 : e11057, 2018
PubMed
8) Nagano M, Matsumoto J : A case of TAFRO syndrome with a large mediastinal mass treated with debulking surgery. Surg Case Rep 2 : 61, 2016
 
9) Kiguchi T, Sato C, Takai K, et al : CT findings in 11 patients with TAFRO syndrome : a variant of multicentric Castleman's disease. Clin Radiol 72 : 905.e1-905.e5, 2017
 
10) Ozawa Y, Yamamoto H, Yasuo M, et al : Two patients with TAFRO syndrome exhibiting strikingly similar anterior mediastinal lesions with predominantly fat attenuation on chest computed tomography. Respir Investig 55 : 176-180, 2017
PubMed
11) Tedesco S, Postacchini L, Manfredi L, et al : Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy-a case report. Exp Hematol Oncol 4 : 3, 2015
 
12) Noda-Narita S, Sumida K, Sekine A, et al : TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim : a case report. CEN Case Rep 7 : 162-168, 2018
PubMed
13) Mizuno H, Sekine A, Oguro M, et al : Renal histology in a patient with TAFRO syndrome : a case report. Hum Pathol 82 : 258-263, 2018
 
14) Noda Y, Saka Y, Kato A, et al : Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage. Clin Nephrol Case Stud 6 : 16-20, 2018
PubMed
15) 伊藤史子, 亀岡吉弘, 奈良美保, ほか : 両側副腎出血を合併したTAFRO症候群. 日本内科学会雑誌 106 : 288-294, 2017
 
16) Nara M, Komatsuda A, Itoh F, et al : Two Cases of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with High Serum Procalcitonin Levels, Including the First Case Complicated with Adrenal Hemorrhaging. Intern Med 56 : 1247-1252, 2017
PubMed
17) Fujiwara Y, Ito K, Takamura A, et al : The first case of thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly (TAFRO) syndrome with unilateral adrenal necrosis : a case report. J Med Case Rep 12 : 295, 2018
PubMed
18) Debatin JF, Spritzer CE, Dunnick NR : Castleman disease of the adrenal gland : MR imaging features. AJR Am J Roentgenol 157 : 781-783, 1991
PubMed
19) Shirai T, Onishi A, Waki D, et al : Successful treatment with tacrolimus in TAFRO syndrome : two case reports and literature review. Medicine (Baltimore) 97 : e11045, 2018
PubMed
20) Ma WL, Zhang L, Zhu TN, et al : TAFRO Syndrome - A Specific Subtype of Castleman's Disease in China. Chin Med J (Engl) 131 : 1868-1870, 2018
 
21) Hiramatsu S, Ohmura K, Tsuji H, et al : Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Meneki Gakkai Kaishi 39 : 64-71, 2016
 
22) Yasuda S, Tanaka K, Ichikawa A, et al : Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy. Int J Hematol 104 : 512-518, 2016
PubMed
23) 川端浩 : Castleman病. 血液診療ハンドブック 改訂3版, 大阪, 医薬ジャーナル社, 2015, pp463-475
 
24) Kanda J, Kawabata H, Yamaji Y, et al : Reversible Cardiomyopathy Associated with Multicentric Castleman Disease : Successful Treatment with Tocilizumab, an Anti-Interleukin 6 Receptor Antibody. Int J Hematol 85 : 207-211, 2007
PubMed
25) Man L, Goudar RK : Reversal of cardiomyopathy with tocilizumab in a case of HIV-negative Castleman's disease. Eur J Haematol 91 : 273-276, 2013
 
26) Oka S, Ono K, Nohgawa M : Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements. Clin Case Rep 6 : 644-650, 2018
PubMed
27) Sorvillo F, Mazziotti G, Carbone A, et al : Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue. J Clin Endocrinol Metab 88 : 4818-4822, 2003
 
28) Okumura M, Ujiro A, Otsuka Y, et al : Cardiac arrest caused by rapidly increasing ascites in a patient with TAFRO syndrome : a case report. Acute Med Surg 4 : 344-348, 2017
 
29) 枝廣陽子, 市川訓基, 角南義孝, ほか : 自己免疫性溶血性貧血を合併したTAFRO症候群. 臨床血液 56 : 2346-2350, 2015
 
30) Fujiki T, Hirasawa S, Watanabe S, et al : Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome. CEN Case Rep 6 : 105-110, 2017
 
31) Hashimoto K, Sano T, Honma Y, et al : An autopsy case of TAFRO syndrome with membranoproliferative glomerulonephritis-like lesions. CEN Case Rep 8 : 48-54, 2019
PubMed
32) 伊東慎市, 堤豊, 菊池遼, ほか : Tocilizumab治療後に血栓性微小血管症を発症したTAFRO症候群. 臨床血液 59 : 2432-2437, 2018
 
P.201 掲載の参考文献
1) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
2) Noda-Narita S, Sumida K, Sekine A, et al : TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim : a case report. CEN Case Rep 7 : 162-168, 2018
PubMed
3) Mizuno H, Sekine A, Oguro M, et al : Renal histology in a patient with TAFRO syndrome : a case report. Hum Pathol 82 : 258-263, 2018
 
4) Furuto Y, Hashimoto H, Horiuti H, et al : Membranoproliferative glomerulonephritis-like findings for TAFRO syndrome, associated with an anterior mediastinal tumor : A case report. Medicine (Baltimore) 97 : e11057, 2018
PubMed
5) Noda Y, Saka Y, Kato A, et al : Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage. Clin Nephrol Case Stud 6 : 16-20, 2018
PubMed
6) Kurose N, Mizutani K, Kumagai M, et al : An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Pathol Res Pract 215 : 410-413, 2019
PubMed
7) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
8) 田中敏郎 : 炎症性疾患に対するIL-6阻害療法 : 現状と今後の展開. 日本臨床免疫学会会誌 38 : 433-442, 2015
Medical*Online
9) Shimada Y, Adachi M, Kobayashi N, et al : A superelderly case of TAFRO syndrome treated effectively using corticosteroid hormones. Clin Case Rep 6 : 638-643, 2018
PubMed
10) Ozeki T, Tsuji M, Yamamoto J, et al : Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome. CEN Case Rep 7 : 243-247, 2018
 
11) Ito S, Uchida T, Itai H, et al : Serial Manifestation of Acute Kidney Injury and Nephrotic Syndrome in a Patient with TAFRO Syndrome. Intern Med 57 : 3129-3133, 2018
 
12) Morel G, Mootien J, Guiot P, et al : Anasarca, Fever, Thrombocytopenia, Organomegaly, and Multiorgan Failure in a 24-Year-Old Pregnant Woman. Case Rep Crit Care 2017 : 3871593, 2017
 
13) Shirai T, Onishi A, Waki D, et al : Successful treatment with tacrolimus in TAFRO syndrome : two case reports and literature review. Medicine (Baltimore) 97 : e11045, 2018
PubMed
14) Tsurumi H, Fujigaki Y, Yamamoto T, et al : Remission of Refractory Ascites and Discontinuation of Hemodialysis after Additional Rituximab to Long-term Glucocorticoid Therapy in a Patient with TAFRO Syndrome. Intern Med 57 : 1433-1438, 2018
 
15) Oka S, Ono K, Nohgawa M : Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements. Clin Case Rep 6 : 644-650, 2018
PubMed
16) Tatekawa S, Umemura K, Fukuyama R, et al : Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep 3 : 472-478, 2015
PubMed
17) 小澤孝幸, 小杉智, 鬼頭真依子, ほか : Rituximabが著効したTAFRO症候群と思われるCastleman病類似症例. 臨床血液 55 : 350-355, 2014
 
18) Ma WL, Zhang L, Zhu TN, et al : TAFRO Syndrome - A Specific Subtype of Castleman's Disease in China. Chin Med J (Engl) 131 : 1868-1870, 2018
 
19) Tedesco S, Postacchini L, Manfredi L, et al : Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol 4 : 3, 2015
 
20) Owattanapanich W, Pholmoo W, Pongpruttipan T, et al : High proportion of TAFRO syndrome in Thai adult Castleman's disease patients : a 10-year experience. Ann Hematol 97 : 1019-1026, 2018
 
21) Hiramatsu S, Ohmura K, Tsuji H, et al : Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Meneki Gakkai Kaishi 39 : 64-71, 2016
 
22) Yasuda S, Tanaka K, Ichikawa A, et al : Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy. Int J Hematol 104 : 512-518, 2016
PubMed
23) Fujiwara Y, Ito K, Takamura A, et al : The first case of thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly (TAFRO) syndrome with unilateral adrenal necrosis : a case report. J Med Case Rep 12 : 295, 2018
PubMed
24) Kawabata H, Kotani S, Matsumura Y, et al : Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 52 : 1503-1507, 2013
 
25) Takayama Y, Kubota T, Ogino Y, et al TAFRO Syndrome with Disseminated Intravascular Coagulation Successfully Treated with Tocilizumab and Recombinant Thrombomodulin. Intern Med 57 : 1291-1296, 2018
PubMed
26) Fujiki T, Hirasawa S, Watanabe S, et al : Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome. CEN Case Rep 6 : 105-110, 2017
 
27) Kubokawa I, Yachie A, Hayakawa A, et al : The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease. BMC Pediatr 14 : 139, 2014
 
28) Okumura M, Ujiro A, Otsuka Y, et al : Cardiac arrest caused by rapidly increasing ascites in a patient with TAFRO syndrome : a case report. Acute Med Surg 4 : 344-348, 2017
 
29) Meguri Y, Asada N, Nakasako Y, et al : A case report of TAFRO syndrome successfully treated by immunosuppressive therapies with plasma exchange. Ann Hematol 98 : 537-539, 2019
PubMed
30) 伊東慎市, 堤豊, 菊池遼, ほか : Tocilizumab治療後に血栓性微小血管症を発症したTAFRO症候群. 臨床血液 59 : 2432-2437, 2018
 
31) Hashimoto K, Sano T, Honma Y, et al : An autopsy case of TAFRO syndrome with membranoproliferative glomerulonephritis-like lesions. CEN Case Rep 8 : 48-54, 2019
PubMed
32) Ozawa Y, Yamamoto H, Yasuo M, et al : Two patients with TAFRO syndrome exhibiting strikingly similar anterior mediastinal lesions with predominantly fat attenuation on chest computed tomography. Respir Investig 55 : 176-180, 2017
PubMed
P.208 掲載の参考文献
1) Sakashita K, Murata K, Takamori M : TAFRO syndrome : current perspectives. J Blood Med 9 : 15-23, 2018
PubMed
2) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
3) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
PubMed
4) Kikuchi T, Shimizu T, Toyama T, et al : Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide. Intern Med 56 : 2205-2211, 2017
PubMed
5) Yamaga Y, Tokuyama K, Kato T, et al : Successful treatment with cyclosporin A in tocilizumab-resistant TAFRO syndrome. Intern Med 55 : 185-190, 2016
PubMed
6) Inoue M, Ankou M, Hua J, et al : Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A : a case report. J Clin Exp Hematop 53 : 95-99, 2013
PubMed
7) Takai K, Nikkuni K, Momoi A, et al : Thrombocytopenia with reticulin fibrosis accompanied by fever, anasarca and hepatosplenomegaly : a clinical report of five cases. J Clin Exp Hematop 53 : 63-68, 2013
 
8) Kawashima M, Usui T, Okada H, et al : TAFRO syndrome : 2 cases and review of the literature. Mod Rheumatol 27 : 1093-1097, 2017
PubMed
9) Kubokawa I, Yachie A, Hayakawa A, et al : The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease. BMC Pediatr 14 : 139, 2014
 
10) Fujiwara S, Mochinaga H, Nakata H, et al : Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol 103 : 718-723, 2016
PubMed
11) 小澤孝幸, 小杉智, 鬼頭真依子, ほか : Rituximab が著効したTAFRO症候群と思われるCastleman病類似症例. 臨床血液 55 : 350-355, 2014
 
12) Hiramatsu S, Ohmura K, Tsuji H, et al : Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy. Nihon Rinsho Meneki Gakkai Kaishi 39 : 64-71, 2016
 
13) Yasuda S, Tanaka K, Ichikawa A, et al : Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy. Int J Hematol 104 : 512-518, 2016
PubMed
14) 高井和江, 新國公司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
15) Tadokoro A, Kanaji N, Hara T, et al : An uncharted constellation : TAFRO syndrome. Am J Med 129 : 938-941, 2016
PubMed
16) Masaki Y, Nakajima A, Iwao H, et al : Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases : is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 53 : 79-85, 2013
 
17) Konishi Y, Takahashi S, Nishi K, et al : Successful treatment of TAFRO syndrome, a variant of multicentric Castleman's disease, with cyclosporine A : possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med 236 : 289-295, 2015
 
18) 枝廣陽子, 市川訓基, 角南義孝, ほか : 自己免疫性溶血性貧血を合併したTAFRO症候群. 臨床血液 56 : 2346-2350, 2015
 
19) Takasawa N, Sekiguchi Y, Takahashi T, et al : A case of TAFRO syndrome, a variant of multicentric Castleman's disease, successfully treated with corticosteroid and cyclosporine A. Mod Rheumatol 29 : 198-202, 2019
 
20) Sakashita K, Murata K, Inagaki Y, et al : An anterior mediastinal lesion in TAFRO syndrome showing complete remission after glucocorticoid and tocilizumab therapy. Respirol Case Rep 4 : e00173, 2016
PubMed
21) Allegra A, Rotondo F, Russo S, et al : Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient : A rare case report and review of the literature. Blood Cells Mol Dis 55 : 206-207, 2015
 
22) Tatekawa S, Umemura K, Fukuyama R, et al : Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep 3 : 472-478, 2015
PubMed
23) Jain P, Verstovsek S, Loghavi S, et al : Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol 90 : 1091-1092, 2015
 
24) Tedesco S, Postacchini L, Manfredi L, et al : Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol 4 : 3, 2015
 
25) Kawabata H, Kotani S, Matsumura Y, et al : Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 52 : 1503-1507, 2013
 
26) Iwaki N, Sato Y, Takata K, et al : Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop 53 : 87-93, 2013
 
27) Coutier F, Meaux Ruault N, Crepin T, et al : A comparison of TAFRO syndrome between Japanese and non-Japanese cases : a case report and literature review. Ann Hematol 97 : 401-407, 2018
 
28) 藤本信乃, 川端浩, 小西順, ほか : 「新規疾患 ; TAFRO症候群疾患概念確立のための多施設共同後方視的調査研究」中間解析結果. 日本リンパ網内系学会会誌 56 (suppl) : 87, 2016
Medical*Online

第3章 展望

P.216 掲載の参考文献
1) Castleman B, Iverson L, Menendez VP : Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9 : 822-830, 1956
PubMed
2) Bartoli E, Massarelli G, Soggia G, et al : Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol 73 : 423-426, 1980
PubMed
3) 高井和江, 新國公司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
4) Kawabata H, Kadowaki N, Nishikori M, et al : Clinical Features and Treatment of Multicentric Castleman's Disease : A Retrospective Study of 21 Japanese Patients at a Single Institute. J Clin Exp Hematop 53 : 69-77, 2013
 
5) El-Osta H, Janku F, Kurzrock R : Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra). Mol Cancer Ther 9 : 1485-1488, 2010
 
6) Iwaki N, Fajgenbaum DC, Nabel CS, et al : Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 91 : 220-226, 2016
PubMed
7) Fajgenbaum DC, Langan RA, Japp AS, et al : Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest 129 : 4451-4463, 2019
PubMed
P.218 掲載の参考文献
1) Yoshizaki K, Matsuda T, Nishimoto N, et al : Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74 : 1360-1367, 1989
 
2) Nishimoto N, Sasai M, Yoshizaki K, et al : Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95 : 56-61, 2000
 
3) van Rhee F, Rossi JF, Fajgenbaum DC, et al : International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132 : 2115-2124, 2018
PubMed
4) Fajgenbaum DC, Shilling D, van Rhee F, et al : Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach. Blood 130 (suppl 1) : 3593, 2017
 
5) Shilling D, Kobrin DM, Fajgenbaum DC : Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome. Blood 132 (suppl 1) : 1121, 2018
 
P.225 掲載の参考文献
1) 吉崎和幸, 岡本真一郎, 川端浩, ほか : キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017
 
2) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : A report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
 
3) キャッスルマン病診療ガイドライン 令和2年度初版 (https://castleman.jp/content/files/guideline_20201118.pdf)
 
4) キャッスルマン病患者会ホームページ (https://www.eonet.ne.jp/~castleman/index.html). Accessed 2021 July 14.
 
P.231 掲載の参考文献
1) Castleman B, Iverson L, Menendez VP : Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9 : 822-830, 1956
PubMed
2) Fajgenbaum DC, van Rhee F, Nabel CS : HHV-8-negative, idiopathic multicentric Castleman disease : novel insights into biology, pathogenesis, and therapy. Blood 123 : 2924-2933, 2014
PubMed
3) 吉崎和幸, 岡本真一郎, 川端浩, ほか : キャッスルマン病診療の参照ガイド. 臨床血液 58 : 97-107, 2017
 
4) 井出眞 : 日本における国際キャッスルマン病研究団体 (CDCN) との連携について. 成人病と生活習慣病 48 : 1365-1369, 2018
Medical*Online
5) CDCNホームページ. https://www.cdcn.org
 
6) Yoshizaki K, Matsuda T, Nishimoto N, et al : Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74 : 1360-1367, 1989
 
7) Nishimoto N, Sasai M, Shima Y, et al : Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95 : 56-61, 2000
 
8) 高井和江, 新國公司, 渋谷宏行, ほか : 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の線維化を認める血小板減少症. 臨床血液 51 : 320-325, 2010
 
9) 吉崎和幸 : キャッスルマン病の疫学診療実態調査と患者団体支援体制の構築に関する調査研究. キャッスルマン病の疫学診療実態調査と患者団体支援体制の構築に関する研究 平成27年度総括・分担研究報告書. 2016, pp1-11
 
10) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
PubMed
11) Herrada J, Cabanillas F, Rice L, et al : The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128 : 657-662, 1998
PubMed
12) Ide M, Kawachi Y, Izumi Y, et al : Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol 76 : 119-123, 2006
 
13) van Rhee F, Fayad L, Voorhees P, et al : Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 28 : 3701-3708, 2010
 
14) 井出眞, 横山倫子, 吉崎和幸 : キャッスルマン病におけるトシリズマブの使い方と注意点. リウマチ科 60 : 124-132, 2018
 
15) van Rhee F, Voorhees P, Dispenzieri A, et al : International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132 : 2115-2124, 2018
PubMed
16) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : a report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
 
17) キャッスルマン病患者会ホームページ. https://www.eonet.ne.jp/~castleman/index.html
 

特別寄稿

P.243 掲載の参考文献
1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956 ; 9 (4) : 822-830.
PubMed
2. Flendrig JA, Schillings PHM. Benign giant lymphoma : the clinical signs and symptoms and the morphological aspects. y. Folia Med Neerl. 1969 ; 12 : 119-120.
 
3. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972 ; 29 (3) : 670-683.
PubMed
4. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978 ; 69 (1) : 86-90.
PubMed
5. Frizzera G, Banks PM, Massarelli G, Rosai J. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol. 1983 ; 7 (3) : 211-231.
 
6. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia : a clinicopathologic study of 16 cases. Hum Pathol. 1985 ; 16 (2) : 162-172.
PubMed
7. Lachant NA, Sun NC, Leong LA, Oseas RS, Prince HE. Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol. 1985 ; 83 (1) : 27-33.
 
8. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995 ; 86 (4) : 1276-1280.
 
9. Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly [in Japanese]. Rinsho Ketsueki. 2010 ; 51 (5) : 320-325.
PubMed
10. Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016 ; 91 (2) : 220-226.
PubMed
11. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 ; 129 (12) : 1646-1657.
PubMed
12. Dispenzieri A, Armitage JO, Loe MJ, et al. The clinical spectrum of Castleman's disease. Am J Hematol. 2012 ; 87 (11) : 997-1002.
 
13. Cohen AB, Swaminathan A, Wang X, et al. Clinical characteristics, treatment patterns, and overall survival of realworld patients with idiopathic multicentric Castleman disease. J Clin Oncol 39, 2021 (suppl 15 ; abstr 7048).
 
14. Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum. 2011 ; 41 (2) : 95-105.
PubMed
15. Fajgenbaum D et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade-refractory idiopathic multicentric Castleman disease. JCI. 2019 ; 129 (10) : 4451-4463.
PubMed
16. Fajgenbaum D. Chasing My Cure : A Doctor's Race to Turn Hope Into Action (Ballantine). 2019
 

書評

最近チェックした商品履歴

Loading...